Podcasts about MSI

Deze talkshow wordt mede mogelijk gemaakt door MSI. Alle meningen in deze video zijn onze eigen. MSI heeft inhoudelijk geen inspraak op de content en zien de video net als jullie hier voor het eerst op de site.Ga maar lekker zitten voor het traditionele startschot van het weekend. Anderhalf uur aan luid gekwebbel over videogames zal straks je trommelvliezen gaan kietelen. Jasper, JJ en Skate zitten in de studio klaar. Ready om een nieuwe editie op te nemen van Einde van de Week Live. De talkshow waarin we elke week het belangrijkste game gerelateerde nieuws met jullie, de kijkers, doornemen. En we hebben een fijn lijstje aan topics voor je klaarstaan. Zo discussiëren de drie over het door ons al voorspelde uitstel van GTA 6. We moeten er nog ruim een jaar op gaan wachten. De drie spreken over de nieuwe Xbox reclame, de houding van Naughty Dog ten aanzien van multiplayer games en de nieuwe trailer van Metroid Prime 4. Dit alles en meer zie en hoor je voorbijkomen in de Einde van de Week Live van vrijdag 7 november 2025.Nog ruim een jaar wachten op de release van GTA 6Jasper, JJ en Skate kijken in deze aflevering ook naar een groot  aantal games waarvan een onderzoeksbureau had aangegeven dat deze rijp waren voor een remake of remaster. Heeft dit bureau gelijk of trappen de drie heren het verhaal direct onderuit?Pak 100 euro en gratis rugzak bij aankoop MSI Vector 16 HX gaming laptopDeze week zet MSI de MSI Vector 16 HX in de schijnwerpers. Een gaming laptop met een Intel Core Ultra 7 processor, een NVIDIA GeForce RTX 5070 Ti, een QHD+ 240Hz display, een 1TB SSD en een 24-zone RGB toetsenbord. De Vector 16 HX kun je nu hier bij MeGekko aanschaffen met een fijne korting en een gratis backpack.Mis nooit meer een bezoeker of pakketje dankzij de Hue deurbelMis geen bezoeker of pakketje met de Philips Hue videodeurbel. Of ontvang meldingen op je telefoon als er iemand voor je deur staat of langsloopt. Dankzij de scherpe 2K-video en Starlight-technologie zie je 24 uur helder en scherp wat er voor je deur gebeurd. En ja, er is ook de mogelijkheid om via de deurbel te communiceren. Wil je meer info hebben over de Hue deurbel dan kun je dat hier aantreffen.Timestamps:00:00:00 Einde van de Week Live van 7 november!00:08:58 Huishoudelijke mededeling: MSI00:12:55 GTA 6 is (weer) uitgesteld. 00:16:16 Een geschiedenis van het uitstel van Rockstar.00:24:25 Xbox is de sjaak.00:31:00 De Gamekings GIG Guide van november.00:44:36 Ryse of Hydra uitgesteld. 00:45:50 Andere cijfers Take Two. 00:50:35 Naughty Dog gaat even geen Multiplayer games meer maken. 00:51:46 Nieuwe 'This is a Xbox' trailer. 00:53:59 Game Pass 2026.01:04:30 BULLETTÎME: PHILIPS HUE 01:08:21 Remasteren of niet?01:15:14 Where Winds Meet. 01:18:27 Nieuwe trailer van Metroid Prime. 01:19:53 Het programma van de Korea trip!01:27:08 Dark Souls serie nu 39 miljoen keer over de toonbank gegaan.01:28:41 Steam Deck scherm kan nu ook uit bij downloaden.01:30:17 World of Warcraft komt niet naar de consoles.01:32:04 Hoe houdt Obsidian zijn personeel aan boord01:34:09 Basketballer Donovan Mitchell over NBA2k26.

Diventa un supporter di questo podcast: clicca qui.➨ Iscrivetevi al nostro canale Telegram: clicca quiNel primo contributo proponiamo la deposizione, in qualità di imputato, di Valerio Fioravanti (Bologna, 22 dicembre 1993) nel corso di un'udienza del secondo appello per la strage del 2 agosto 1980. Nel secondo contributo (Roma, 10 novembre 1989), durante un'udienza del processo d'appello per la strage di Bologna, Fioravanti racconta alla Corte i dettagli dell'assalto a Radio Città Futura, avvenuto a Roma il 9 gennaio 1979.Si ringrazia Radio radicale per la condivisione dei reperti. Tra i principali temi toccati durante le deposizioni: 1) «I vecchi gruppi? Hanno lavorato per anni e non hanno prodotto niente»; 2) «Ci hanno attribuito 35 omicidi. E c'è un motivo se sono stati fatti»; 3) «Nessuno dei pentiti Nar ha detto qualcosa sulla strage di Bologna»; 4) Sulla teoria della «banda super segreta»; 5) «Non bisogna confondere un gruppo misterioso come Avanguardia nazionale con un gruppo esplicito, noto, dissezionato in tutti i modi»; 6) «Il pregiudizio verso di noi? Essere troppo giovani per aver fatto tutto da soli»;  7) «Dopo Acca Larentia volevamo vendicarci del Msi»; 8) «Le 250 mila pagine di atti processuali? Strategia della confusione»; 9) Sulla vicenda delle cartelle cliniche di Massimo Sparti; 10) «La strage? Ho una mia idea»; 11) Sul «tatuaggio» di Picciafuoco; 12) «Il nostro controllo sulla piazza romana? Non attraverso i libri»; 13) L'azione a Radio città futura; 14) I «messaggi verso destra» e verso «la sinistra». 

Featuring perspectives from Dr Kathleen N Moore and Dr Matthew A Powell, including the following topics: Introduction: A Pan-tumor Perspective on Microsatellite Instability (MSI)-High Disease — Immunotherapy for Localized Disease (0:00) Case: A woman in her early 60s with mismatch repair-deficient metastatic endometrial cancer (EC) and multiple positive metastases — Shachar Peles, MD (8:18) Case: A woman in her mid 60s with recurrent EC and a BRCA mutation — Stephen "Fred" Divers, MD (12:17) Data Review: Immune Checkpoint Inhibitors (15:26) Case: A woman in her early 30s with Stage I mismatch repair-proficient EC and multiple pulmonary metastases after receiving fertility treatments — Kellie E Schneider, MD (28:22) Case: A woman in her early 80s with EC and high blood pressure — Syed F Zafar, MD (34:24) Case: A postmenopausal woman in her late 60s with recurrent HER2-positive EC and unresectable carcinomatosis — Lyndsay J Willmott, MD (38:18) Case: A woman in her late 60s with EC and pericarditis — Karim ElSahwi, MD (44:28) Data Review: Novel Antibody-Drug Conjugates (51:38) Case: A woman in her early 70s with metastatic MSI-stable, HER2-negative EC with PI3 kinase and FGFR mutations wants to avoid treatment with chemotherapy — Victoria Giffi, MD (55:01) CME information and select publications

Intel muscle sa communication avant la sortie de sa nouvelle génération de puces Panther Lake. Le géant américain des semi-conducteurs vient d'annoncer l'ouverture de cinq boutiques éphémères, à Séoul, New York, Londres, Munich et Paris. Une opération de séduction mondiale, pensée à la fois pour se rapprocher du grand public, montrer ses innovations et, accessoirement, marquer les esprits avant les fêtes de fin d'année.La première de ces boutiques a ouvert ses portes le 30 octobre à Munich, et donne un avant-goût de ce que les visiteurs parisiens découvriront à partir du 5 novembre. Selon le site spécialisé NotebookCheck, ce “pop-up” allemand présente une large gamme d'ordinateurs portables équipés des nouvelles puces Lunar Lake et Arrow Lake, les fers de lance d'Intel pour 2025. Les plus grands constructeurs répondent à l'appel : HP, Lenovo, Dell, ASUS, Acer, MSI, LG ou encore Samsung. Ces magasins éphémères ne se limitent pas à l'exposition : les visiteurs peuvent tester les machines et repartir directement avec.Intel met également en avant ses Chromebook et ses ordinateurs professionnels, comme les Lenovo ThinkPad ou HP EliteBook, destinés aux entreprises. Mais à Paris, l'expérience se voudra plus immersive. L'enseigne Boulanger s'associe à l'opération pour proposer des démonstrations interactives autour de l'intelligence artificielle : détection de deepfakes, outils de productivité, ou encore génération de contenu en temps réel. Le “Intel Experience Store” parisien ouvrira ses portes du 5 au 30 novembre, au 14 boulevard Poissonnière, dans le neuvième arrondissement. Une adresse symbolique, au cœur d'un quartier bouillonnant de tech et de culture numérique. Pour Intel, l'enjeu est double : raviver sa proximité avec le public à l'heure où la concurrence s'intensifie, notamment avec AMD et Apple, et rappeler que le PC reste un terrain d'innovation. Entre vitrines spectaculaires et vitrines commerciales, ces boutiques sont autant de laboratoires d'image destinés à repositionner Intel au centre du jeu. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

In this episode of the Oncology Brothers podcast, we dived into the key takeaways from ESMO 2025, focusing on gastrointestinal (GI) malignancies. Join us as we welcomed Dr. Rachna Shroff, a GI medical oncologist from the University of Arizona, to discuss the latest studies and their implications for clinical practice. Episode Highlighted: •⁠  ⁠ctDNA in Colorectal Cancer: DYNAMIC-III and PEGASUS studies, examining the evolving role of ctDNA as a prognostic and potential predictive tool in early-stage colon cancer. •⁠  ⁠STELLAR-303: Learn about the promising results of immunotherapy in refractory MSI-stable colorectal cancer and the associated toxicities. •⁠  ⁠MATTERHORN: Updated data on durvalumab with FLOT in the perioperative setting is changing the standard of care for upper GI malignancies. •⁠  ⁠FORTITUDE-101 Study: FGFR2b target in metastatic gastric and GE junction adenocarcinoma. Tune in for an insightful discussion that highlights the latest advancements in oncology and their potential impact on patient care.  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to check out our previous episodes for more insights on conference highlights, recent approvals, and treatment algorithms. #ESMO2025 #GIOcology #ctDNA #ColorectalCancer #Immunotherapy #OncologyBrothers #PrecisionMedicine

Send us a textCan one AI system learn from every organ — and teach us something new about all of them?In this edition of DigiPath Digest #31, I explore how artificial intelligence is transforming pathology across multiple organ systems, revealing connections that help us diagnose faster, more consistently, and more accurately than ever before.From glomerulonephritis to hepatocellular carcinoma, AI is no longer confined to a single specialty — it's becoming the connective tissue between them.What's Inside:1️⃣ AI for Bladder Cancer Classification We begin with a multicenter study validating AI models for urothelial neoplasm classification using over 12,000 whole-slide images. Both CNNs and transformer models achieved high accuracy (AUC 0.983, F1 score 0.9). I discuss why the F1 score matters — and what it tells us about model balance between sensitivity and specificity.2️⃣ AI in Colorectal Cancer Care Next, we explore multimodal AI — integrating histopathology, radiology, genomics, and blood markers to modernize colorectal cancer workflows. AI now helps detect adenomas, infer microsatellite instability (MSI) from H&E slides, and predict treatment outcomes. I highlight the critical need for external validation, interpretability, and governance as AI enters clinical use.3️⃣ AI for Glomerular Nephritis Diagnosis A deep learning model trained on over 100,000 kidney biopsy images identified four nephritis types — FSGS, IgA, MN, and MCD — with over 85% accuracy. This technology could ease workloads and improve turnaround time in renal pathology. Still, I share why AI support may feel both empowering and unsettling for many pathologists.4️⃣ AI in Liver Disease (MASLD & HCC) AI is advancing noninvasive fibrosis staging and risk prediction in liver pathology. From large consortia like NIMBLE and LITMUS to predictive models for HCC therapy response, AI is moving us closer to precision hepatology. I also discuss the challenge of translating these tools from research to regulatory approval.5️⃣ Lightweight AI for Domain Generalization Finally, we look at one of pathology AI's biggest challenges: domain shift — when a model trained on one scanner or staining style performs poorly elsewhere. The new Histolite framework shows how lightweight, self-supervised models can generalize across data sources — trading some accuracy for reliability in real-world use.My TakeawayAcross every study, a single message stands out: AI isn't replacing pathologists — it's amplifying our vision. By connecting kidney, colon, liver, and bladder insights, AI is teaching us that medicine works best when it learns across boundaries.Episode HighlightsBladder cancer AI validation (06:41)Multimodal colorectal AI (12:38)Glomerular nephritis deep learning (19:29)AI in liver pathology (29:55)Domain shift & Histolite framework (38:17)Halloween wrap-up + SITC preview (46:18)Join me next time for updates from the SITC 2025 Conference, where I'll be live at Booth 415 with Hamamatsu and Biocare, discussing how AI and spatial biology are converging to drive clinical utility.#DigitalPathology #AIinHealthcare #ComputationalPathology #CancerDiagnostics #LiverPathology #RenalPathology #FutureOfMedicine #DigiPathDigestSupport the showGet the "Digital Pathology 101" FREE E-book and join us!

##

Deze talkshow wordt mede mogelijk gemaakt door MSI. Alle meningen in deze video zijn onze eigen. MSI heeft inhoudelijk geen inspraak op de content en zien de video net als jullie hier voor het eerst op de site.Ga maar lekker zitten voor het traditionele startschot van het weekend. Anderhalf uur aan luid gekwebbel over videogames zal straks je trommelvliezen gaan kietelen. Jelle, JJ en Koos zitten in de studio klaar. Ready om een nieuwe editie op te nemen van Einde van de Week Live. De talkshow waarin we elke week het belangrijkste game gerelateerde nieuws met jullie, de kijkers, doornemen. En we hebben een fijn lijstje aan topics voor je klaarstaan. Zo discussiëren de drie over de slechte public reviews van Battlefield REDSEC. Ze praten over de Matrix-game die Kojima niet mocht maken van Konami. En ze bespreken het gerucht over de komst van de derde trailer voor GTA 6. Dit alles en veel, veel meer ga je voorbij zien en horen komen in de Einde van de Week Live van vrijdag 31 oktober 2025.Gamers zijn niet bepaald lief voor Battlefield REDSECAndere onderwerpen in deze talkshow zijn onder meer de bekendmaking van de drie genomineerden voor de Dutch Game Awards, Halo dat gebruikt/misbruikt wordt door ICE in de VS en een nieuwe Crash Bandicoot TV serie op Netflix.Scoor 50 euro korting op de Sword 17 HX gaming laptop van MSIOok deze week zet MSI de nieuwe Sword 17 HX gaming laptop in de schijnwerpers. Deze laptop bevat een Intel® Core™ i7-14700HX processor, een NVIDIA® GeForce RTX 4060™ GPU, 1 TB SSD en een 7 inch WUXGA beeldscherm. Al met al een prima tool om de meeste nieuwe games te kunnen spelen. De Sword 17 HX is hier met 50 euro korting te krijgen bij Paradigit.Wat kan Philips Hue verlichting doen voor jouw concentratie en slaapritmeDat de verlichting van Philips Hue de sfeer in en om jouw woning kan verhogen, dat moge bekend zijn. Bij Gamekings gebruiken veel van de hosts de lampen zelf thuis. Maar dat licht zaken als jouw concentratievermogen en slaapritme kan verbeteren is misschien nieuw. Check hier alle mogelijkheden die Hue jou biedt.Timestamps:00:00:00 Einde van de Week Live van 31 oktober00:03:58 Huishoudelijke mededeling: MSI00:08:46 Battlefield REDSEC krijgt vooral negatieve reviews.00:13:32 DICE heeft ook de controversiële skin weggehaald00:16:10 Kojima had een Matrix-game kunnen maken.00:18:19 Hij is er weer: Half-Life 3 nieuws van Tyler McVicker.00:22:22 Steeds meer bedrijven integreren AI in het maken van games00:29:29 GTA op de 25 jarige verjaardag van de PS2 in de VS (26 oktober) 00:35:00 Dutch Game Awards 2025, 3 december Chasse Theater Breda00:42:27 Is de Forza Motorsport franchise nu verdwenen?00:44:29 Amerikaanse ICE gebruikt Halo in hun communicatie.00:53:58 BULLETTÎME: PHILIPS HUE01:06:01 Call of Duty film is bevestigd.01:07:05 Bully Online01:08:20 Er komt een Crash Bandicoot tv serie01:10:04 Over TV series gesproken. Seizoen vier van The Witcher scoort goede reviews. 01:10:44 27 feb komt Resident Evil Requiem uit, ook op de Switch 2.01:11:00 Over controllers gesproken 01:16:22 Sega's advertentie

Featuring an interview from Dr John Strickler, including the following topics: Prognostic value of molecular residual disease (MRD) as detected by circulating tumor DNA (ctDNA) and optimal incorporation of MRD assays into the care of patients with colorectal cancer (0:00) Potential use of MRD assays for patients with microsatellite instability (MSI)-high localized colorectal cancer or those with delayed progression or metastatic disease (16:09) Tumor-informed MRD assays under clinical development (20:36) Predictive role of ctDNA in Stage III colon cancer treated with celecoxib; effect of low-dose aspirin on response to celecoxib in patients with PI3K pathway alterations (24:19) Case: A man in his late 50s with resected Stage IIA colon cancer (30:06) Case: A woman in her late 40s with Lynch syndrome and MSI-H colon cancer with a solitary, small hepatic metastasis (34:57) MRD as a future clinical trial endpoint for solid tumors; increasing incidence of colorectal cancer in younger people (40:24) Antibody-drug conjugates in the treatment of colorectal cancer (45:13) Perspectives on promising areas of clinical research in colorectal cancer (48:23) CME information and select publications

En este nuevo episodio de AutoFM se sientan a la mesa Antonio R. Vaquerizo, Javier Quilón, Rubén Gómez y Fernando Rivas, junto a Sandra Zorrilla, periodista e influencer del motor, y Alberto Dorsch, director comercial y de marketing de Toyota Kobe Motor. Además, se suman por videollamada José Lagunar y Alex Moya para completar un programa lleno de actualidad, análisis y debate sobre el presente y futuro del automóvil. El programa arranca con una pregunta que nos acompaña cada vez más a menudo en 2025: ¿en qué se ha convertido realmente el coche? Unos lo siguen viendo como una necesidad, otros como un lujo, y algunos creen que ha perdido la pasión que lo hacía especial. Con Sandra Zorrilla aportando una visión más emocional y Alberto Dorsch representando la parte racional pero apasionada del sector, analizamos si hoy se compra coche con la cabeza o con el corazón, y cómo ha cambiado nuestra forma de vivir el mundo del motor. Después nos centramos en Toyota y sus últimas novedades. Hablamos del nuevo Toyota C-HR eléctrico, un modelo clave en la estrategia de electrificación de la marca, y del Toyota Aygo X Cross híbrido, que da un paso adelante en el segmento urbano con una propuesta eficiente y práctica. Comentamos su diseño, tecnología, precios y lo que suponen dentro de la gama Toyota, apoyándonos en los vídeos de presentación de ambos modelos. Miramos también hacia Alemania para decir adiós al Volkswagen Touareg, que afronta la recta final de su comercialización tras 22 años de historia. Repasamos sus generaciones, cómo evolucionó desde aquel SUV robusto y de lujo compartido con Porsche y Audi, y qué papel ha jugado dentro de la gama Volkswagen. Una despedida a un coche que marcó un antes y un después en la marca. En nuestra sección de Seguridad Vial con Hyundai, José Lagunar nos cuenta por videollamada todo lo que ha visto en el Congreso de Investigación de Accidentes de Tráfico de Cesvimap, donde se han realizado pruebas de sistemas ADAS, crash tests con coches eléctricos y simulaciones de impacto con motos. Una sección para entender mejor cómo la investigación y la tecnología están salvando vidas cada día. En el Buzón del oyente, Javier Quilón lee el mensaje de Ignacio Arribas Lanchares, que nos plantea una duda muy real: cómo asegurar correctamente a un niño de 7 años en un autobús con cinturón de tres puntos cuando no se puede usar una sillita infantil. Analizamos el caso y damos las recomendaciones adecuadas para garantizar la seguridad infantil incluso fuera del coche particular. Seguimos con una noticia empresarial importante: EBRO anuncia su llegada a Bulgaria en 2026. Explicamos por qué la histórica marca española apuesta por este país como primer paso de su expansión internacional, y qué puede significar este movimiento dentro de su estrategia de crecimiento y posicionamiento europeo. A continuación, contamos la entrega muy especial de un Toyota GR Supra A90 Final Edition realizada por Toyota Kobe Motor en las instalaciones de MSI de Teo Martín. Una oportunidad para recordar que el Toyota GR Yaris sigue a la venta y repasar las nuevas instalaciones de Toyota Kobe Majadahonda, un espacio moderno que refuerza el compromiso de la marca con la experiencia del cliente y la deportividad. Conectamos después con Alejandro Moya para la Sección AutoScout24, donde exploramos el mundo de los súper SUVs. Analizamos tres modelos impresionantes: el Jeep Grand Cherokee SRT8, el BMW X6M preparado por AC Schnitzer y el Volvo XC90 V8 Sport, con un bonus muy especial, el Volkswagen Touareg W12. Potencia, exclusividad y carácter se mezclan en una sección llena de curiosidades y cifras que hacen soñar a los amantes de los grandes todoterrenos deportivos. Rubén Gómez nos trae “Las curiosidades más curiosas”, con una historia insólita: un hombre en Australia que circulaba con un jacuzzi en el techo de su coche. A partir de este caso repasamos qué multas aplicaría la DGT en España y debatimos sobre los mayores disparates que hemos hecho o transportado alguna vez en nuestros coches. Una sección divertida y sorprendente para cerrar el bloque con humor y reflexión. Y terminamos con la Sección TOTALENERGIES, donde hablamos con Antonio Fernández sobre los lubricantes agrícolas y off-road. Descubrimos qué tipo de aceites se usan en tractores, maquinaria pesada y equipos de obra pública, por qué no sirven los mismos que en los turismos y cómo la tecnología de los lubricantes ha evolucionado para proteger motores que trabajan en condiciones extremas. Un cierre técnico pero muy interesante para completar un programa lleno de contenido, pasión y actualidad del motor. Escúchanos en: www.podcastmotor.es Twitter: @AutoFmRadio Instagram: autofmradio Twitch: AutoFMPodcast Youtube: @AutoFM Contacto: info@autofm.es

Send us a text00:00 Brought to You By TAB Quartz00:19 Intro00:29 Latino Fabricator Group Meets November in San Antonio01:58 A Word from TAB Quartz03:08 ParkFest 2025 a Success05:56 Brazil Promotes Stone in United States07:07 NSI Lundh Honor to Stony Creek's Atkinson08:25 New Digs for UMI Stone, MSI, Neolith10:32 LX Hausys Issues ESG Report11:40 Neolith Achieves Sustainability Award12:38 MSI Rated as Admired Workplace13:37 Outro14:05 Brought to You By TAB QuartzRadio Stone Update is presented on the second and fourth Wednesdays every month at 9 a.m. everywhere on Earth with the latest news and insights in hard surfaces. Check our archives at www.radiostoneupdate.com.

Unbox comfort at https://rovelab.com/Wanshow and get $200 off with any sofa and bed purchase for a limited time. Sit back, relax, and enjoy M1. Do you want a spooky upgrade this spooky season? Head over to https://bit.ly/3KvEgMB to enter AMD's newest sweepstakes to win one of the five AMD Ryzen 9 9950X3D Processors! Thanks to MSI for sponsoring this episode! Head over to https://lmg.gg/JIYiq and check out their MAG X870E TOMAHAWK WIFI Motherboard Support a great cause with Green Man Gaming! Check out their Destiny 2 Charity Bundle using our link: https://bit.ly/4nPuKlU Get a Circuit Board skin for your device so dbrand can keep messing with Linus at https://dbrand.com/pcb Check out Dell's powerful business laptops at: https://lmg.gg/dellprowan Pick up a Secretlab Titan Evo Ergonomic Gaming Chair today at: https://lmg.gg/secretlabwan Get a special deal on Private Internet Access VPN today at https://www.piavpn.com/LinusWan Purchases made through some store links may provide some compensation to Linus Media Group. Learn more about your ad choices. Visit megaphone.fm/adchoices

El nuevo Nvidia DGX Spark promete un petaflop de potencia y 128 GB de memoria unificada, capaz de ejecutar modelos de IA gigantes en tu escritorioPor Félix Riaño @LocutorCo  Si te gusta la tecnología y quieres entender el futuro de los mini PC, búscame en Flash Diario en Spotify.   Nvidia acaba de lanzar el DGX Spark, un computador tan pequeño que cabe en una mano, pero tan potente que puede ejecutar modelos de inteligencia artificial con 200.000 millones de parámetros. Cuesta 4.000 dólares, pesa apenas 1,2 kilogramos y consume 240 vatios, lo mismo que una bombilla potente.La presentación oficial coincidió con una escena poco común: Jensen Huang, el CEO de Nvidia, llevó personalmente el primer Spark a Elon Musk en las instalaciones de SpaceX, en Texas, justo antes del ensayo número 11 del cohete Starship. Según Nvidia, el Spark no está pensado para videojuegos ni para uso doméstico, sino para desarrolladores, investigadores y creadores que necesiten potencia de supercomputador sin depender de la nube. Su promesa es poner la inteligencia artificial “al alcance de la mano”.  Pequeño por fuera, pero con cerebro de cohete espacial.El DGX Spark es, literalmente, un supercomputador de escritorio. Mide apenas 15 por 15 centímetros y 5 centímetros de grosor. Dentro lleva el nuevo chip GB10 Grace Blackwell Superchip, una combinación de CPU Arm de 20 núcleos y GPU Blackwell con el poder de una RTX 5070. Su sistema operativo no es Windows, sino DGX OS, una versión personalizada de Ubuntu Linux llena de herramientas para inteligencia artificial.Nvidia lo describe como “el supercomputador de IA más pequeño del mundo”, capaz de alcanzar un petaflop, es decir, un millón de billones de operaciones por segundo. Y lo mejor: puedes enchufarlo en un tomacorriente normal y tener potencia de centro de datos en tu mesa de trabajo.Durante años, los desarrolladores de inteligencia artificial tuvieron que alquilar tiempo en la nube para entrenar modelos grandes. Eso implicaba pagar mes a mes, esperar colas y depender de servidores remotos. Los computadores personales simplemente no tenían memoria suficiente ni conectividad adecuada para manejar tantos datos.El DGX Spark quiere cambiar esa historia. Con sus 128 GB de memoria unificada y NVLink-C2C para cinco veces más ancho de banda que PCIe 5, puede ejecutar modelos locales como Flux.1 de Black Forest Labs para generar imágenes, Cosmos Reason para visión computacional o Qwen3 para crear chatbots. Aun así, queda la duda: ¿cuántas personas podrán pagar 4 000 dólares por un mini PC que no trae Windows ni está pensado para jugar?Nvidia está apostando a que sí. Quiere que cada estudiante, investigador y creador tenga su propio laboratorio de IA en el escritorio. Por eso abrió el hardware a socios como Acer, Asus, Dell, HP, Lenovo y MSI, que lanzarán sus propias versiones del Spark. La idea es democratizar la potencia de la IA sin depender de la nube.Además, Nvidia prepara un modelo mayor, el DGX Station, una torre de escritorio con el chip GB300 Grace Blackwell Ultra que va a llegar a finales de año. Mientras tanto, el pequeño Spark ya está en laboratorios de robótica, universidades y estudios de arte digital, donde empiezan a usarlo para entrenar modelos sin internet ni latencia. Y sí, la versión que recibió Elon Musk fue autografiada por Jensen Huang.El primer DGX Spark se entregó a Musk en la base de SpaceX en Texas, justo cuando se preparaba el undécimo vuelo de Starship. Nvidia aprovechó la escena para recordar que ya en 2016 le había dado a OpenAI su primer DGX-1, una máquina que costaba 129.000 dólares y medía más de 85 centímetros. Hoy, el Spark cuesta una treintava parte y es 20 veces más pequeño.Con su peso de 1,2 kilogramos y sus 200 Gb/s de conectividad, puede conectarse a otros Sparks para trabajar en equipo, como si fueran bloques de LEGO de supercomputación. Las reseñas especializadas ya lo llaman “freaking cool” y “un laboratorio en una caja”. En otras palabras, Nvidia no solo vendió un PC, sino una fantasía para los que soñaban con tener su propio centro de datos en el escritorio.  El DGX Spark de Nvidia transforma el concepto de computador personal con potencia de supercomputador por 4.000 dólares. Aunque no es para todos, marca el inicio de una nueva generación de IA local.  Si te gusta la tecnología y quieres entender el futuro de los mini PC, búscame en Flash Diario en Spotify.  Nvidia lanza el DGX Spark: un mini supercomputador de 4.000 dólares con 1 petaflop de potencia y 128 GB de memoria.  

Kebaktian 1 Minggu XVIII Sesudah PentakostaGKP Jemaat BandungMinggu, 12 Oktober 2025 pukul 07.00 WIBTema : "Menyadari Keberadaan Diri Sendiri"Bacaan Alkitab : Lukas 17-11-19Pelayan Firman : Pdt. Fierdhaus Y. Nyman, MSi.@GKP Bandung Oktober 2025

Jeremy and Brett could not make it (not to be confused with renowned British actor Jeremy Brett), but the show must go on! A shorter, and probably worse version, but a version nonetheless.  Some topics still got covered though!Timestamps:00:00 Intro01:18 Patreon02:24 Food with Josh04:18 AMD partners with OpenAI, offers 10% of the company16:14 NVIDIA partners with xAI17:07 Qualcomm acquires Arduino18:37 Synology drops self-branded HDD requirement20:44 be quiet! expands Light Base case lineup22:01 Help us OOBE Wan Kenobi, local accounts are our only hope24:17 MSI says their 800 Series boards are future CPU ready29:46 (In)Security Corner minus Jeremy and Brett36:15 Gaming Quick Hits45:58 Picks of the Week53:51 Outro ★ Support this podcast on Patreon ★

JCO PO author Dr. Asaf Maoz at Dana-Farber Cancer Institute shares insights into article, “Causes of Death Among Individuals with Lynch Syndrome in the Immunotherapy Era.” Host Dr. Rafeh Naqash and Dr. Maoz discuss the causes of death in individuals with LS and the evolving role of immunotherapy. TRANSCRIPT Dr. Rafeh Naqash: Hello, and welcome to JCO Precision Oncology Conversations, where we bring you engaging conversations with authors of clinically relevant and highly significant JCOPO articles. I'm your host, Dr. Rafeh Naqash, podcast editor for JCO Precision Oncology and Associate Professor Medicine, at the OU Health Stephenson Cancer Center. Today, I'm super thrilled to be joined by Dr. Asaf Maoz, Medical Oncologist at Dana-Farber Cancer Institute, Brigham and Women's Hospital, and faculty at the Harvard Medical School, and also lead author on the JCO Precision Oncology article entitled "Causes of Death Among Individuals with Lynch Syndrome in the Immunotherapy Era." This publication will be a concurrent publication with an oral presentation at the annual CGA meeting. At the time of this recording, our guest's disclosures will be linked in the transcript. Asaf, I'm excited to welcome you on this podcast. Thank you for joining us today. Dr. Asaf Maoz: Thank you so much for highlighting our paper. Dr. Rafeh Naqash: Absolutely. And I was just talking to you that we met several years back when you were a trainee, and it looks like you've worked a lot in this field now, and it's very exciting to see that you consider JCOPO as a relevant home for some of your work. And the topic that you have published on is of significant interest to trainees from a precision medicine standpoint, to oncologists in general, covers a lot of aspects of immunotherapy. So, I'm really excited to talk to you about all of this. Dr. Asaf Maoz: Me too, me too. And yeah, I think JCOPO has great content in the area of cancer genetics and has done a lot to disseminate the knowledge in that area. Dr. Rafeh Naqash: Wonderful. So, let's get started and start off, given that we have hosts of different kinds of individuals who listen to this podcast, especially when driving from home to work or back, for the sake of making everything simple, can we start by asking you what is Lynch syndrome? How is it diagnosed? What are some of the main things to consider when you're trying to talk an individual where you suspect Lynch syndrome? Dr. Asaf Maoz: Lynch syndrome is an inherited predisposition to cancer, and it is common. So, we used to think that, or there's a general notion in the medical community that it is a rare condition, but we actually know now from multiple studies, including studies that look at the general population and do genetic testing regardless of any clinical phenotype, that Lynch syndrome is found in about 1 in 300 people in the general population. If you think about it in the United States, that means that there are over a million people living with Lynch syndrome in the United States. Unfortunately, most individuals with Lynch syndrome don't know they have Lynch syndrome at the current time, and that's where a lot of the efforts in the community are being made to help detect more individuals who have Lynch syndrome. Lynch syndrome is caused by pathogenic germline variants in mismatch repair genes, MLH1, MSH2, MSH6, or PMS2, or as a result of pathogenic variants in EPCAM that cause silencing of the MSH2 gene. Dr. Rafeh Naqash: Excellent. Thank you for that explanation. Now, one of the other things I also realized, similar to BRCA germline mutations, where you require a second hit for individuals with Lynch syndrome to have mismatch repair deficient cancers, you also require a second hit to have that second hit result in an MSI-high cancer. Could you help us understand the difference of these two concepts where generally Lynch syndrome is thought of to be cancers that are mismatch repair deficient, but that's not necessarily true for all cases as we see in your paper. Can you tease this out for us a little bit more? Dr. Asaf Maoz: Of course, of course. So, the germline defect is in one of the mismatch repair genes, and these genes are responsible for DNA mismatch repair, as their name implies. Now, in a normal cell, we think that one working copy is generally enough to maintain the mismatch repair machinery intact. What happens in tumors, as you alluded to, is that there is a second hit in the same mismatch repair gene that has the pathogenic germline variant, and that causes the mismatch repair machinery not to work anymore. And so what happens is that there is formation of mutations in the cancer cell that are not present in other cells in the body. And we know that there are specific types of mutations that are associated with defects in mismatch repair mechanisms, and those are associated a lot of times with frameshift mutations. And we have termed them ‘microsatellites'. So there are areas in the genome that have repeats, for example, you know, if you have AAAA or GAGA, and those areas are particularly susceptible to mutations when the mismatch repair machinery is not working. And so we can measure that with DNA microsatellite instability testing. But we can also get a sense of whether the mismatch repair machinery is functioning by looking at protein expression on the surface of cancer cells and by doing immunohistochemistry. More recently, we're also able to infer whether the mismatch repair machinery is working by doing next-generation sequencing and looking at many, many microsatellites and whether they have this DNA instability in the microsatellites. Dr. Rafeh Naqash: Excellent explanation. As a segue to what you just mentioned, and this reminds me of some work that one of my good friends, collaborators, Amin Nassar, whom you also know, I believe, had done a year and a half back, was published in Cancer Cell as a brief report, I believe, where the concept was that when you look at these mismatch repair deficient cancers, there is a difference between NGS testing, IHC testing, and maybe to some extent, PCR testing, where you can have discordances. Have you seen that in your clinical experience? What are some of your thoughts there? And if a trainee were to ask, what would be the gold standard to test individuals where you suspect mismatch repair deficient-related Lynch syndrome cancers? How would you test those individuals? Dr. Asaf Maoz: We do sometimes see discordance, you know, from large series, the concordance rate is very high, and in most series it's over 95%. And so from a practical perspective, if we're thinking about the recommendation to screen all colorectal cancer and all endometrial cancer for mismatch repair deficiency, I think either PCR-based testing or immunohistochemistry is acceptable because the concordance rate is very high. There are rare cases where it is not concordant, doing multiple of the tests makes sense at that time. If you think about the difference between the tests, the immunohistochemistry looks at protein expression, which is a surrogate for whether there is mismatch repair deficiency or not, right? Because ultimately, the mismatch repair deficiency is manifested in the mutations. So if the PCR does not show microsatellite instability and now NGS does not show microsatellite instability, the IHC may be a false positive. At the end of the day, the functional analysis of whether there are actually unstable microsatellites either by PCR or by NGS is what I would consider more informative. But IHC again is an excellent test and concordant with those results in over 95% of cases. Now there is also an issue of sampling. It's possible that there's heterogeneity within the tumor. We published a case in JCOPO about heterogeneity of the mismatch repair status, and that was both by immunohistochemistry, but also by PCR. So there are some caveats and interpreting these tests does require some expertise, and I'm always happy to chat with trainees or whoever has an interesting or challenging case. Dr. Rafeh Naqash: Thanks again for that very easy to understand explanation. Now going to management strategies, could you elaborate a little bit upon the neo-adjuvant data currently, or the metastatic data which I think more people are familiar with for immunotherapy in individuals with MSI-high cancers? Dr. Asaf Maoz: Yeah, that's an excellent question and obviously a very broad topic. Individuals with Lynch syndrome typically develop tumors that are mismatch repair deficient or microsatellite unstable. And we have seen over the last 15 years or so that these tumors, because they have a lot of mutations and because these mutations are very immunogenic, we have seen that they respond very well to immunotherapy. And this has been shown across disease sites and has been shown across disease settings. And for that reason, immunotherapy was approved for MSI-high or mismatch repair deficient cancer regardless of the anatomic site. It was the first tissue-agnostic approval by the FDA in 2017. And so there are exciting studies both in the metastatic setting where we see individuals who respond to immunotherapy for many years, and one could wonder whether their cancer is going to come back or not. And also in the earlier setting, for example, the Cercek et al. study in the New England Journal from Sloan Kettering, where they showed that neoadjuvant immunotherapy can cause durable responses for rectal cancer that is mismatch repair deficient. And in that series, the patients did not require surgery or radiation, which is standard of care for rectal cancer otherwise. And there's also exciting data in the adjuvant space, as was presented in ASCO by Dr. Sinicrope, the ATOMIC study, and many more efforts to bring immunotherapy into the treatment landscape for individuals with MSI-high cancer, including individuals with Lynch syndrome. Dr. Rafeh Naqash: A lot of activity, especially in the neo-adjuvant and adjuvant space over the last two years or so. Now going to the actual reason why we are here is your study. Could you tell us why you looked at this idea of patients who had Lynch syndrome and died, and the reasons for their death? What was the thought that triggered this project? Dr. Asaf Maoz: As we were talking about, we now know that immunotherapy really has changed the treatment landscape for individuals with Lynch syndrome, and that most cancers that individuals with Lynch syndrome do have this mismatch repair deficiency. But we also know that individuals with Lynch syndrome can develop tumors that do not have mismatch repair deficiency, and we call them mismatch repair proficient or microsatellite stable. And there was a series from Memorial Sloan Kettering showing that in colorectal cancer, about 10% of the tumors that individuals with Lynch syndrome developed did not have mismatch repair deficiency. In addition to that, we anecdotally saw that some of our patients with Lynch syndrome died of causes that were not mismatch repair deficient tumors. We wanted to see how that has changed since immunotherapy was approved in a tissue-agnostic manner, meaning that we could look at this regardless of where the cancer started, because we would anticipate that if the tumor was mismatch repair deficient, the patient would be able to access immunotherapy as standard of care. Dr. Rafeh Naqash: Thank you. And then you looked at different aspects of correlations with regards to individuals that had an MSI-high cancer with Lynch syndrome or an MSS cancer with Lynch syndrome. Could you elaborate on some of the important findings that you identified as well as some of the unusual findings that perhaps we did not know about, even though the sample size is limited, but what were some of the unique things that you did identify through this project? Dr. Asaf Maoz: The first question was what cause is leading to death in individuals with Lynch syndrome? And we had 54 patients that we identified that had died since the approval of immunotherapy in 2017, 44 of which died of cancer-related causes. And when we looked at cancer-related causes of death, we wanted to know how many of those were due to mismatch repair deficient tumors versus mismatch repair proficient tumors or MS-stable tumors. And we found, somewhat surprisingly, that 43% of patients in our cohort actually died of tumors that were microsatellite stable or mismatch repair proficient, meaning of tumors that are not typically associated with Lynch syndrome. This is not entirely surprising as a cause of death because we know that immunotherapy does not typically work for tumors that are microsatellite stable. And so in the metastatic setting, there are much less cases of durable remissions with treatment. But it was helpful to have that figure as an important benchmark. There are previous studies about causes of death in Lynch syndrome, and particularly from the Prospective Lynch Syndrome Database in Europe. Those have provided really important information about cause of death by cancer site, but they typically don't have mismatch repair status and are more difficult to interpret in that regard. They also don't include a large number of individuals who have PMS2 Lynch syndrome, which is the most common, but least penetrant form of Lynch syndrome. Dr. Rafeh Naqash: As far as the subtype of pathogenic germline variants is concerned, did you notice anything unusual? And I've always had this question, and you may know more about this data, is: In the bigger context of immunotherapy, does the type of the pathogenic germline variant for Lynch syndrome associated MSI-high cancers, does that impact or have an association with the kind of outcomes, how soon a cancer progresses or how many exceptional responders perhaps with MSI-high cancers actually have a certain specific pathogenic germline variant? Dr. Asaf Maoz: That's an excellent question, and certainly we need more data in that space. We know that the type of germline mutation, or the gene in which there is a germline pathogenic variant, determines to a large degree the cancer risk, right? So we know that individuals who have germline pathogenic variants in MLH1 or MSH2 have a much higher colorectal cancer risk than, for example, PMS2. We know that for PMS2, the risks are more limited to colorectal and endometrial, and may be lower risk of other cancers. We also know that, you know, the spectrum of disease may change based on the pathogenic germline variants. For example, individuals who have MSH2 associated Lynch syndrome have more risk of additional cancers in other organs like the urinary tract and other less common Lynch-associated tumors. The question about response to therapy is one where we have much less information. There are studies that are trying to assess this, but I don't think the answer is there yet. Some of the non-clinical data looks at how many mutations there are based on the pathogenic variant and what the nature of those mutations are, whether they're more frameshift or others. But I think we still need more clinical data to understand whether the response to immunotherapy differs. It's also complicated by the fact that the immunotherapy landscape is changing, especially in the metastatic setting, now with the approval of combination ipilimumab and nivolumab for first-line treatment of colorectal cancer that is microsatellite unstable. But in our study, we did find that, as you would expect, there is an enrichment in MS-stable cancers among those with PMS2 Lynch syndrome. Again, our denominator is those who died, right? So this is not the best way to look at the question whether this is overall true, that is more addressed by the study that Sloan Kettering published. But we do see, as we would anticipate, that there are more microsatellite stable cancers among those with PMS2 Lynch syndrome that died. Dr. Rafeh Naqash: A lot to uncover there for sure. This study and perhaps some of the other work that you're doing is slowly advancing our understanding of some of these concepts. So I'd like to shift gears to a couple of provocative questions that I generally like to ask. The first is, in your opinion, and you may or may not have data to back this up, which is okay, and that's why we're having a conversation about it. In your opinion, do you think the type or the quality of the neoantigen is different based on the pathogenic germline variant and a Lynch syndrome associated MSI-high cancer? Dr. Asaf Maoz: I think there are some data out there that, you know, I can't cite off the top of my mind, but there are some data out there that suggest that that may be the case. I think the key question is the quality, right? I think that whether these differences that are found on a molecular level also translate to a clinical difference in response is something that is unknown at this moment. Some people hypothesize that if the tumor has less neoantigens, there's less of a response to immunotherapy. But I think we really need to be careful before making those assertions on a clinical level. I do think it's a really important question that needs to be answered, among others because, you know, in the colorectal space, for example, where we have both the option of doing ipilimumab with nivolumab and the option of doing pembrolizumab, we don't really know which patients need the CTLA-4 blockade versus which patients can receive PD-1 blockade alone and avoid the potential excess toxicity of the CTLA-4 blockade. There are a lot of interesting questions there that still need to be answered. And of course, individuals with Lynch syndrome are just a fraction of those individuals who have MSI-high cancer. So there's also the question about whether non-Lynch syndrome associated MSI-high cancer responds differently to immunotherapy than Lynch syndrome associated MSI-high cancer. A lot of very interesting questions in the field for sure. Dr. Rafeh Naqash: Absolutely. My second question is more about trying to understand the role of ctDNA, MRD monitoring in individuals with Lynch syndrome. If somebody has a germline, you know, Lynch syndrome MSI-high cancer, when you do a tumor-informed ctDNA assessment, what do you capture generally there? Because, and this question stems from a discussion I've had with somebody regarding EGFR lung cancer, since I treat individuals with lung cancer, and the concept generally is that even if the tissue showed EGFR, but for MRD monitoring, when you do a barcoded sequence of different tumor specific mutations, it's not actually the EGFR that they track in the blood when they do ctDNA assessment. But from a Lynch syndrome standpoint, if you have a germline, right, which is the first hit, and then you have the somatic in the tumor, which is the second hit, are you aware or have you tried to look into this where what is exactly being followed if one had to follow MRD in a Lynch syndrome MSI-high colorectal cancer? Dr. Asaf Maoz: I think a lot of the MRD assays are proprietary, and so we don't receive information about what the mutations that are being tracked are. In general, the idea is to track mutations that we would not expect to disappear as part of resistant mechanisms. We want these to be truncal mutations. We want these to be mutations in which resistance is not expected to result in reversion mutations. But what specifically is being tracked is something that I don't know because these assays, the tumor-informed ones, are proprietary, and we don't get the results regarding specific mutations. When it's circulating tumor DNA that is not necessarily tumor-informed, we do get those results, but that is less so about the specific selection of mutations. Dr. Rafeh Naqash: Thank you for clarifying that question to some extent, of course, as you said, we don't know a lot, and we don't know what we don't know. That's the most important thing that I've learned in the process of understanding precision medicine and genomics, and it's a very fast-paced evolving field. Last question related to your project, what is the next step? Are you planning any next steps as a bigger multicenter study or validation of some sort? Dr. Asaf Maoz: There are two big questions that this study raises. One, is this true across multiple other sites, right? Because this is a single center study, and we really need additional centers to look at their data and validate whether they are also seeing that a substantial portion of deaths in individuals with Lynch syndrome are attributable to mismatch repair proficient cancer. The other question is whether we can look at specifically MSI-high cancer versus MS-stable cancer and understand what the mortality rate for each of those are. From a clinical perspective, it's important to counsel individuals with Lynch syndrome about general cancer screening outside of mismatch repair deficient tumors and to understand that there is also a risk of mismatch repair proficient tumors and that treatment for those tumors would be different. There's a lot of work to be done in the future. Another major area of need is to see whether tumors that are microsatellite stable can be sensitized to immunotherapy, and that is beyond the Lynch syndrome field, but that is something that certainly would benefit these individuals with Lynch syndrome who develop mismatch repair proficient cancer. Dr. Rafeh Naqash: That's very interesting to hear, and we'll look forward to seeing some of those developments shape in the next few years. Now, I'd like to spend a minute, minute and a half on you specifically as a researcher, clinician, scientist. Could you briefly highlight - because I remember meeting you several years back as a trainee, with your interest in genomics, computational research - could you briefly tell us what led you to hereditary cancer syndromes based on your research and work? What are some of the things that you learned along the way that other early career investigators can perhaps take lessons from? Dr. Asaf Maoz: Big questions there, thanks for asking. I got interested in the field of hereditary cancer syndromes when I came to the United States and started doing lab research in Stephen Gruber's lab at the time at USC. He's now at City of Hope. And my interest was originally looking at immunotherapy and immunology, but I went to the case conferences where we were learning about individuals with hereditary cancer, and those were kind of earlier days where we were still trying to figure out how to test and what the implications for these individuals would be. And through fellowship, I was also very interested in that, and I did my senior fellowship years with Dr. Yurgelun here at Dana-Farber, who is the director of the Lynch Syndrome Center. And I I think it's the combination between being able to treat individuals based on precision medicine and what the germline mutation is, but also the ability to prevent cancer and to develop strategies to intercept cancer early that is really appealing to me in this field. It's also a great field to be in because it's a small field. If you come to the CGA-IGC meeting, you'll be able to interact with everyone. Everyone is super collaborative, super nice, and I really recommend it to trainees. The CGA-IGC annual meeting is really a great opportunity to learn more and experience some of the advancement specifically in the GI hereditary space. Lessons for trainees. I think there are a lot of lessons that I could think about, but I think finding strong and supportive mentors is one of the things that has helped me most. I think that just having close relationship with your mentor, having frequent discussions and honest discussions about what is feasible, what is going to make a difference for your patients and your research and what you want to focus on is really important. And so I think if I had to choose one thing, I would say choose a mentor that you trust, that you feel you have a good relationship with, and that has the availability to support you. Dr. Rafeh Naqash: Thank you so much for those insightful comments, and thank you for sharing with us your journey, your project, and some of your interesting thoughts on this concept of hereditary cancers. Hopefully, we'll see more of this work being published in JCOPO through your lab or work from others. Dr. Asaf Maoz: Thank you so much. I appreciate the opportunity to be here. Dr. Rafeh Naqash: Thank you for listening to JCO Precision Oncology Conversations. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at ASCO.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Deze talkshow wordt mede mogelijk gemaakt door MSI. Alle meningen in deze video zijn onze eigen. MSI heeft inhoudelijk geen inspraak op de content en zien de video net als jullie hier voor het eerst op de site.Het weekend komt eraan. Als je goed kijkt, zie je hem al aan de horizon verschijnen. De hoogste tijd dus om een goed potje te gaan chillen. Het ‘verheugen op' het weekend doen we zoals tijd met het maken van een nieuwe aflevering van Einde van de Week Live. De talkshow waarin we aan het einde van de werkweek het belangrijkste game gerelateerde nieuws met jullie doornemen. In deze episode hebben Daan, Jelle en Koos het onder andere over het cancellen van een nieuw deel uit de Assassin's Creed-reeks, de chaos rond de prijs van Xbox Game Pass en de launch van Battlefield 6. Deze onderwerpen en meer ga je zien en horen in de Einde van de Week Live van vrijdag 10 oktober 2025.Ubisoft cancelt uit angst voor ophef nieuw deel van Assassin's CreedAndere onderwerpen in deze video zijn de prijsverlaging van ARC Raiders, de nieuwe trailer van het nieuwe seizoen van The Witcher op Netflix, de geheel door AI geproduceerde game van Elon Musk en een nieuw editie van Cool of Serious Uncool.Check de razendsnelle Stealth A16 Mercedes/AMG AI gaming laptop van MSDeze week zet MSI de Stealth A16 AMG Mercedes gaming laptop in de schijnwerpers. Het betreft hier geen gewone Stealth A16, maar een vlotte en unieke samenwerking tussen Stealth en AMG Design. Onder de motorkap bevinden zich een AMD Ryzen AI 9 processor, een NVIDIA GeForce RTX 5070 videokaart, een 2TB SSD, een QHD+ 240Hz  OLED display (dus net zo snel als een Mercedes) en een per key RGB toetsenbord. Een fijne laptop om op te gamen en te werken. Of tijdens het werk te gamen. Deze laptop kun je hier nu scherp geprijsd verkrijgen.      Krijg 20% korting op de gehele collectie bij ReellReell is de kleding-sponsor van Gamekings. Toffe, no nonsens kleding, beschikbaar tegen een scherpe prijs. Die prijs gaan we speciaal voor de community van Gamekings nog scherper maken. Er is een nieuwe drop, nieuwe looks en de herfst/winter collectie van Reell staat online. Jij kunt 20% exclusieve korting krijgen op de gehele collectie met code ‘gamekings' via reellworld.com. Kun je goed gekleed de winter in.Scoor kaarten voor het concert van Disturbed in de Ziggo DomeOp dinsdag 14 oktober aanstaande treedt de Amerikaanse alternative metal band Disturbed op in de Ziggo Dome te Amsterdam. Deze beukende band staat bij onder andere JJ standaard op afspeellijst tijdens het trainen. Disturbed is onder andere bekend van hun nummer ‘Down with the Sickness', en hun tracks zitten in tientallen games waaronder Project Gotham Racing 4, Tony Hawk Underground 2 en Fortnite. Hier kun je de kaarten voor het concert scoren.

Review các phim ra rạp từ ngày 03/10/2025CHỊ NGÃ EM NÂNG – T13Đạo diễn: Vũ Thành VinhDiễn viên: Lê Khánh, Quốc Trường, Thuận Nguyễn, Uyển ÂnThể loại: Gia đình, Hài, Tâm LýChị Ngã Em Nâng là câu chuyện cảm động xoay quanh hai chị em Thương và Lực – lớn lên trong một gia đình gắn bó với nghề làm nhang truyền thống. Biến cố xảy ra từ sớm khiến Thương trở thành chỗ dựa duy nhất cho em trai, vừa làm chị, vừa gánh vai trò của cha mẹ. Lớn lên trong điều kiện không đủ đầy, nhưng với bản lĩnh cùng những lời dạy ăn sâu vào tâm thức mà cha mẹ dành cho Thương, cô đã kiên trì đầy nghị lực để quyết tâm thay đổi cuộc sống. Thương thành công và kỳ vọng em trai đi theo con đường mình đã lựa chọn. Tuy nhiên, sự áp đặt vô tình tạo nên rạn nứt, đẩy hai chị em vào những mâu thuẫn sâu sắc – thậm chí đến mức đối mặt sinh tử.TAY ANH GIỮ MỘT VÌ SAO - KĐạo diễn: Kim Sung HoonDiễn viên: Lee Kwang Soo, Hoàng Hà, Duy Khánh, Cù Thị Trà, Um Mun Suk, Lâm Thanh Mỹ,...Thể loại: Hài, Tình cảmSiêu sao Kang Jun Woo – “Hoàng tử Châu Á” – rơi vào tình cảnh “mắc kẹt” tại Việt Nam sau một loạt sự cố dở khóc dở cười, nơi anh gặp Thảo – một cô gái bán cà phê đầy đam mê, quyết tâm theo đuổi ước mơ của mình.AVATAR: DÒNG CHẢY CỦA NƯỚC (CHIẾU LẠI) – T13Đạo diễn: James CameronDiễn viên: Sam Worthington, Zoe Saldana, Dương Tử Quỳnh,...Thể loại: Hành Động, Khoa Học Viễn Tưởng, Phiêu LưuAvatar: Dòng Chảy Của Nước tái chiếu tạo rạp DUY NHẤT 01 TUẦN từ 03.10.2025 với định dạng 3D - IMAX 3D và cả 4DX 3D Nhất định không thể bỏ lỡ trải nghiệm điện ảnh này, lưu lịch đặt vé ngay!NHÂN DIỆN – T16Đạo diễn: Yeon Sang-hoDiễn viên: Shin Hyun-been, Park Jeong-min, Han Ji-hyun, Kwon Hae-hyo, Im Seong-jaeThể loại: Hồi hộpIm Dong-hwan, chàng trai chưa từng biết mặt mẹ mình, bàng hoàng khi cảnh sát thông báo đã tìm thấy hài cốt của bà – người mất tích suốt 40 năm – với nghi ngờ bị sát hại. Anh quyết tâm đi tìm sự thật cùng nữ đạo diễn Kim Soo-jin, người đang thực hiện phim tài liệu về cha anh – nghệ nhân làm dấu mù lòa từ khi sinh ra. Họ lần theo ký ức của những người từng làm việc với bà tại xưởng may năm xưa, để dần vén màn bí mật được chôn giấu suốt bốn thập kỷ.CẬU BÉ CÁ HEO VÀ BÍ MẬT 7 ĐẠI DƯƠNGThể loại: Hoạt HìnhDưới lòng đại dương xanh thẳm, Cậu Bé Cá Heo - người hùng được cả biển cả yêu thương lại day dứt với câu hỏi mình là ai và đến từ đâu, nhưng chưa kịp tìm ra lời giải thì kẻ thù cũ đã trở lại, tạo nên quái vật cua khổng lồ gieo rắc hiểm nguy lên đảo và biển sâu. Trước thử thách lớn nhất đời mình, cậu phải vừa tìm ra sự thật về bản thân, vừa sát cánh cùng những người bạn thân thiết để bảo vệ thế giới đại dương yên bình, mở ra một hành trình kỳ thú tràn ngập màu sắc, tiếng cười và những thông điệp đẹp đẽ về tình bạn, tình cảm gia đình và lòng dũng cảm.ENHYPEN VR CONCERT : IMMERSIONThể loại: Hòa nhạcMột lời hẹn ước đầy bí ẩn từ ENHYPEN gửi đến ENGENE. “Anh sẽ mãi mãi ở bên cạnh em.” Tiếng thì thầm dịu dàng vang vọng trong những hành lang xa lạ. Rồi một cánh cửa mở ra - để ranh giới giữa thực tại và ảo mộng dần dần lu mờ. Một văn phòng trải dài vô tận, một nhà máy bị lãng quên, một sân thượng nơi hai vầng trăng hồng và đỏ cùng hiện hữu - trong những không gian không ngừng biến chuyển ấy, bạn sẽ khám phá những khía cạnh của ENHYPEN mà họ chưa từng bộc lộ…. Từ những bản hit toàn cầu như “Bite Me” và “XO (Only If You Say Yes)”, đến ca khúc fan song đầy chan chứa trong “Highway 1009”, mỗi sân khấu đều là sự hòa quyện giữa những bài hát kinh điển và một trải nghiệm khó quên được tạo ra chỉ dành riêng cho các fan yêu quý - ENGENE. Với những khung hình choáng ngợp và màn trình diễn mê hoặc lòng người, sân khấu của ENHYPEN bừng tỉnh ngay trước mắt bạn... chỉ với khoảng cách 0 inch, trong không gian VR. Tại ranh giới của IMMERSION, một thế giới hoàn toàn mới đang chờ đợi bạn. Hãy bước vào đó ngay bây giờ!--------------------------------------------------#8saigon #reviewphimrap #tayanhgiumotvisao #chingaemnang #phimnhandien

Enhance your setup with the XENEON EDGE at: https://corsair.com/xeneon-edge Go to http://FactorMeals.com/WAN50OFF and use code WAN50OFF to get 50% off your first box, plus Free Breakfast for 1 Year. (Offer only valid for new Factor customers with code and qualifying auto-renewing subscription purchase.) Unbox comfort at https://rovelab.com/Wanshow and get an exclusive $100 discount for our audience, on top of other website offers for the next 72 hours. Sit back, relax, and enjoy M1. Get a Circuit Board skin for your device so dbrand can keep messing with Linus at https://dbrand.com/pcb Check out Dell's powerful business laptops at: https://lmg.gg/dellprowan Pick up a Secretlab Titan Evo Ergonomic Gaming Chair today at: https://lmg.gg/secretlabwan Get a special deal on Private Internet Access VPN today at https://www.piavpn.com/LinusWan Purchases made through some store links may prThanks to MSI for sponsoring this episode! Check out their Codex R2 AI PC at https://lmg.gg/M0V8z Whether you need a wedding ring, anniversary ring, or you just want a ring that looks awesome, head over to https://www.thorum.com and code WAN to get 20% off a truly unique ring Visit https://www.squarespace.com/WAN and use offer code WAN for 10% off Level up your streaming and recording game with XSplit Broadcaster! Get 30% off your first purchase or subscription with code WANSHOW30 at https://lmg.gg/xsplitwan Get a Circuit Board skin for your device so dbrand can keep messing with Linus at https://dbrand.com/pcb Check out Dell's powerful business laptops at: https://lmg.gg/dellprowan Pick up a Secretlab Titan Evo Ergonomic Gaming Chair today at: https://lmg.gg/secretlabwan Get a special deal on Private Internet Access VPN today at https://www.piavpn.com/LinusWan Purchases made through some store links may provide some compensation to Linus Media Group. Learn more about your ad choices. Visit megaphone.fm/adchoices

Deze talkshow wordt mede mogelijk gemaakt door MSI. Alle meningen in deze video zijn onze eigen. MSI heeft inhoudelijk geen inspraak op de content en zien de video net als jullie hier voor het eerst op de site.Het weekend dringt zich naar voren. Nog één avondje slapen en dan is het zover. Tijd om te chillen en de boel even de boel te laten. Dat ‘verheugen op' gaan we versterken zoals alleen wij dat kunnen met een nieuwe editie van Einde van de Week Live. De talkshow waarin we elke zeven dagen het belangrijkste game gerelateerde nieuws met jullie doornemen. In deze episode hebben Jelle, JJ en Koos het onder andere over de even verrassende als forse prijsverhoging van Xbox Game Pass, de komst van Battlefield 6 en het getrol van EA richting Activision en de schrijver van de The Witcher 4-boeken die niet alles aan de gelijknamige games tot vindt. Deze topics en meer ga je zien en horen in de Einde van de Week Live van vrijdag 3 oktober 2025.Prijzen Xbox Game Pass rijzen de pan uitWat bezielt Xbox om de prijzen van Game Pass opeens te verdubbelen? Dat vroeg iedereen, en dus ook wij, zich af toen het nieuws woensdag bekend werd gemaakt. En waarom gaat Square Enix sleutelen aan de gameplay van Final Fantasy VII Rebirth Part III. Deze vragen worden beantwoord in deze video.Check de brute kracht van de Titan 18 HX Dragon Edition gaming laptopDeze week zet MSI hun absolute paradepaardje in de spotlights: de Titan 18 HX Dragon edition. Ga er maar even voor zitten, want deze laptop heeft onder de motorkap een Intel Core Ultra 9 HX Processor, een RTX 5090 videokaart, een 18” 4K 120Hz panel, een 24-zone RGB toetsenbord, 96GB RAM intern geheugen en een 6 TB SSD. De Titan 18 HX is geen goedkope jongen, maar dan heb je ook wat. Echt elke game en elke creator software draait hier soepel op. Interesse, je kunt hier alle info vinden.Scoor kaarten voor concert The Architects in Ziggo DomeVolgende week dinsdag (7 oktober) kun je de moshpit in bij het optreden van de Britse metalcore band The Architects. Ze treden dan op in de Ziggo Dome in Amsterdam. De Britten groeien momenteel snel in populariteit. Na twee jaar touren met Metallica zijn ze klaar om op eigen benen te staan in Europa. Dat ze populair zijn, kun je ook afmeten aan de vele tracks van de band die in videogames. Denk aan Rock Band, Guitar Hero, Watch Dogs, Fortnite, Forza Horizon 5 en WWE 2K25 verschenen. Hier kun je de tickets scoren.

This week on the podcast we go over our reviews of the be quiet! Dark Mount Gaming Keyboard and the SK hynix Platinum P51 Gen5 Solid State Drive.  We also discuss MSI's Project Zero GPU, the APNX V2 PC Case, Electronic Arts being acquired, the Battlefield 6 Season 1 roadmap, and more!

Management Systems International, LLC, organizer of the new MSI's Online Courses for a Variety of ISO Topics, announced their Online Leadership Workshop event will be held in Online on Available as of Oct 1, 2025 Management Systems International, LLC City: Carlsbad Address: 300 Carlsbad Village Dr Ste 108A #421 Website: https://msi-international.com/ Phone: +1 760 434 9141 Email: dprocter@msi-international.com

Deze talkshow wordt mede mogelijk gemaakt door MSI. Alle meningen in deze video zijn onze eigen. MSI heeft inhoudelijk geen inspraak op de content en zien de video net als jullie hier voor het eerst op de site.Het weekend komt eraan. Morgen is het zover. En dat kan vandaag maar één ding betekenen. Inderdaad, we gaan dat weekeinde feestelijk inluiden met een nieuwe editie van Einde van de Week Live. De talkshow waarin we elke week het belangrijkste game gerelateerde nieuws met jullie, de kijkers doornemen. Deze aflevering wordt een speciale, want hij staat geheel in het teken van Tokyo en de Tokyo Game Show. Vol warme en nostalgische gevoelens kijken we naar al het nieuws wat de afgelopen dagen op ons af is gekomen. Met aan tafel Koos en Jelle. Twee hosts die beide vorig jaar zelf in de Makuhara Messe aanwezig waren. Hoe kijken ze terug op vorig jaar en wat vinden ze van het nieuws dat nu uit Tokyo komt. De PlayStation State of Play, de trailer van Kojima's OD, de aankondigingen van Capcom en ga zo maar door. Dit alles en meer ga je zien en horen in de Einde van de Week Live van vrijdag 26 september 2025. Inclusief een dot Wasabi.Hoe goed was de PlayStation State of Play?Einde van de Week draait niet alleen om het bespreken van al het nieuws. Lol maken is ook een belangrijk onderdeel. En die lol ga je volop voorbij zien en horen komen in deze uitzending. Bijvoorbeeld in een Japans getinte editie van Cool & Serious Uncool. Schenk dus maar snel een glaasje sake in.Krijg 250 euro korting op de Katana 15 HX gaming laptopDeze week zet MSI opnieuw de Katana 15 HX in de spotlights. Een krachtige gaming laptop met aan boord een 14e generatie Intel Core i7 HX processor, een RTX 5060 videokaart, een 15.6” 144Hz display, een 512GB SSD en een 4-zone RGB toetsenbord. De Katana 15 HX is momenteel hier bij BOL verkrijgbaar met een lekkere 250 euro korting.Timestamps:00:00:00 Einde van de Week Live van 26 september!00:01:14 Huishoudelijke mededeling: MSI00:05:04 Tokyo Game Show00:15:26 Kojima, en de trailer van OD, op de Tokyo Game Show.00:24:35 De hoogtepunten van de PlayStation State of Play.00:34:54 Nieuwe trailer van Pragmata getoond tijdens TGS 00:37:38 Xbox kondigt aan dat Forza Horizon 6 zich in Japan zal afspelen.00:41:18 Tweede grote aankondiging van Xbox was Gungrave GORE Blood Heat. 00:43:47 Tokyo Game Show voedselcollaborations. 00:49:10 Metal Gear Solid Delta: Snake Eater Fox Hunt mode komt eind oktober.00:55:36 ROG Ally X prijs en releasedatum bekendgemaakt.00:58:50 Voorjaar 2026 worden dure maanden dankzij GTA 6.01:00:56 Er komt een Nintendo pop-up store in Lond

The Trump administration is cutting off or moving funding for TRIO, GEAR UP, and MSI programs—even though Congress approved the money. Hosts Mushtaq Gunja, Jon Fansmith, and Sarah Spreitzer explain what's happening, why it matters, and what colleges should do next. ACE President Ted Mitchell also joins to discuss the need to protect free expression and civil dialogue on campus following the murder of Charlie Kirk. Here are some of the links and references from this week's show:  U.S. Department of Education Ends Funding to Racially Discriminatory Discretionary Grant Programs at Minority-Serving Institutions  Department of Education | September 10, 2025  Trump Administration Delays $660M for College Access Programs  Inside Higher Ed | September 12, 2025  Trump Redirects Millions to Historically Black Colleges, Charter Schools  The New York Times (sub. req.) | September 15, 2025  RESTRICTION ON ENTRY OF CERTAIN NONIMMIGRANT WORKERS   White House | September 19, 2025  Trump to Impose $100,000 Fee Per Year for H-1B Visas, in Blow to Tech  Reuters | September 20, 2025  White House Tries to Tamp Down Corporate Panic for High-skill Visa Holders after Last-minute Overhaul  Politico | September 20, 2025 

Deze talkshow wordt mede mogelijk gemaakt door MSI. Alle meningen in deze video zijn onze eigen. MSI heeft inhoudelijk geen inspraak op de content en zien de video net als jullie hier voor het eerst op de site.Drie heren zitten klaar achter de desk, te weten Huey, Jasper en Koos. Zij gaan jullie een nieuwe episode van Einde van de Week Live voorschotelen. De talkshow waarin we wekelijks het belangrijkste game gerelateerde nieuws met jullie doornemen. Met dit keer onder andere de speelsessie van Jasper met de grootste map van Battlefield 6. Is de game klaar voor launch? Verder praten de drie over de nieuwe details over Assassin's Creed: Black Flag Remake, de komst van de beta van Call of Duty Black Ops 7 en de 'controverse' over de hoge moeilijkheidsgraad van Hollow Knight: Silksong. Dit en veel andere gespreksonderwerpen zie en hoor je voorbij komen in de Einde van de Week Live van vrijdag 19 september 2025.De releasedatum van Battlefield 6 nadert snelAndete onderwerpen in EvdWL zijn onder meer een mogelijke nieuwe Like a Dragon-game, de verrassende nieuwe game van Bohemia Interactive en de casting van de belangrijkste karakters in de Mass Effect tv-serie.Krijg 250 euro korting op de Katana 15 HX gaming laptopDeze week zet MSI opnieuw de Katana 15 HX in de spotlights. En met een goede reden. De Katana 15 HX is een krachtige gaming laptop die namelijk gebruik maakt van de nieuwste 14e generatie Intel Core i7 HX processor. Dit terwijl de vergelijkbare laptops van de concurrentie vaak een 13e generatie i7 processor of een AMD Ryzen 7 bevatten. Je krijgt dus de beste performance. Ter ondersteuning van dit statement van MSI hebben we de benchmarks voor je klaarstaan. Verder bevat de laptop een RTX 5060 videokaart, een 15.6” 144Hz display, een 512GB SSD en een 4-zone RGB toetsenbord. De Katana 15 HX is momenteel hier bij BOL verkrijgbaar met 250 fijne euro's korting: https://msi.gm/S36E5F1C .Zet je eigen PC in elkaar tijdens de EZ DIY Workshop van MSIOp 4 oktober organiseert MSI in samenwerking met Paradigit in Eindhoven een zogenaamde EZ DIY (Easy, Do It Yourself) Workshop. Mocht je van plan zijn een nieuwe desktop te willen kopen, dan kan kun je die nu in de webshop van Paradigit samenstellen, waarna hij die dag voor je klaarligt. De PC wordt vervolgens met de hulp van PC-experts stap voor stap in elkaar gezet. Na afloop heb je dus een dikke PC die werkt én je weet voor de volgende keer hoe je het zelf kan doen. Interesse? Meld je hier aan: https://www.paradigit.nl/powered-by-msi/diy-workshop/ .Timestamps:00:00:00 Einde van de Week Live van 19 september00:00:20 Huishoudelijke mededeling: MSI00:03:02 Nog een huishoudelijke mededeling: Playstation Top 10 item.00:05:53 Nieuwe maps en modes in Battlefield 6; een teaser van Jasper.00:11:03 Call of Duty Black Ops 7 closed en open beta komen respectievelijk 2 en 5 oktober.00:13:41 Nieuwe details over de Assassin's Creed: Black Flag Remake. 00:23:32 Ryu Ga Gotoku Studio komt al snel met een nieuwe Like a Dragon game.00:26:51 Developer Hollow Knight: Silksong reageert op hoge moeilijkheidsgraad. 00:30:15 Bohemia Interactive heeft het bij hun nieuwe IP over een andere boeg gegooid.00:32:00 BULLETTÎME: MSI00:35:43 Mass Effect hoofdrolspelers zijn gelekt is.00:38:43 Schietlood voor memes nu Borderlands 4 het moeilijk heeft qua technische prestaties. 00:42:36 Dit bericht van de Arnhemse game-expert...00:45:52 Nieuwe geanimeerde tv-serie gebaseerd op de Splinter Cell franchise00:48:46 Nintendo Direct trok meer kijkers dan het Apple event.01:03:49 Deze man spaart alles van Super Mario en heeft inmiddels meer dan 500 Mario games.01:08:33 Meta komt met de Meta Ray-Ban Display AI bril.01:11:28 Cool of Serious Uncool?

Deze talkshow wordt mede mogelijk gemaakt door MSI. Alle meningen in deze video zijn onze eigen. MSI heeft inhoudelijk geen inspraak op de content en zien de video net als jullie hier voor het eerst op de site.Het weekend staat voor de deur. En dat kan maar één ding betekenen. Inderdaad, je krijgt een nieuwe editie  op te van Einde van de Week Live voor de spreekwoordelijke kiezen. De talkshow waarin we elke week het belangrijkste game gerelateerde nieuws met jullie, de kijkers doornemen. Deze aflevering wordt een speciale, want naast een uur gezellig gekwebbel over de laatste nieuwtjes en roddels, kijken we ook mee naar de Nintendo Direct. Plus een korte nazit natuurlijk. Een bomvolle editie dus die ook ingaat op het bizarre patent van Nintendo dat de game-wereld in de greep heeft, de launch van Borderlands en de eerste details van de battle royale mode van Battlefield 6. Dit alles en meer ga je zien en horen in de Einde van de Week Live van vrijdag 12 september 2025.Heeft de Nintendo Direct ons blij gemaakt?In deze uitzending komt Kevin ook even langs. Er staan immers nog een paar losse eindjes open wat Hollow Knight: Silksong open. Is de game beter dan zijn voorganger en vanwaar de hype? Plus wat Kevin dat er straks bij de Nintendo Direct getoond wordt?Krijg 250 euro korting op de Katana 15 HX gaming laptopDeze week zet MSI de Katana 15 HX in de spotlights. Een krachtige gaming laptop met aan boord een 14e generatie Intel Core i7 HX processor, een RTX 5060 videokaart, een 15.6” 144Hz display, een 512GB SSD en een 4-zone RGB toetsenbord. De Katana 15 HX is momenteel hier bij BOL verkrijgbaar met een lekkere 250 euro korting.Pak 600 korting op de 32-inch GS95UV-B monitor van LG UltraGearDe LG UltraGear OLED 32GS95UV-B monitor is de monitor waar Koos thuis zijn games op speelt. Op dit bakbeest speel je games met in een 4K resolutie met een verversingssnelheid van 240 hertz. Deze monitor is hier bij Coolblue tijdelijk met 600 euro korting te krijgen. Een niet misselijke aanbieding die we jullie niet wilden onthouden. Op = wel op.

Immunotherapy is not usually effective against pancreatic cancer (PC), but a new study published in Oncotarget (Volume 16, 2025) highlights rare cases where it did help. These examples, though uncommon, may offer valuable insights for future treatment. Pancreatic Cancer and Immunotherapy Pancreatic cancer is often diagnosed at an advanced stage, which limits treatment options and contributes to its poor prognosis. While chemotherapy remains the standard treatment, it usually offers only modest benefits in terms of survival. Immunotherapy—an approach that activates the immune system to fight cancer—has been effective in other cancers but has shown limited success in PC. This is largely due to the tumor's ability to suppress immune responses and create an environment that protects it from attack. Currently, these drugs are only approved for a small subset of patients whose tumors have a specific genetic feature called high microsatellite instability (MSI-high), found in just 1 to 2 percent of cases. The Study: Pancreatic Cancer Immunotherapy Responders The study, titled “Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence,” was led by first author Kavin Sugumar and corresponding author Jordan M. Winter, from University Hospitals Seidman Cancer Center. The researchers examined medical records from 14 patients with pancreatic ductal adenocarcinoma (PDAC) who had responded unexpectedly well to immune checkpoint inhibitors—drugs that help reactivate immune cells to attack cancer. The drugs included PD-1 inhibitors such as pembrolizumab and nivolumab, CTLA-4 inhibitors like ipilimumab, and agents targeting tumor-associated macrophages. To find these rare cases, the research team contacted 471 oncologists from 91 major U.S. cancer centers between 2020 and 2021. Full blog - https://www.oncotarget.org/2025/09/11/immunotherapy-response-in-pancreatic-cancer-what-a-new-study-reveals/ Paper DOI - https://doi.org/10.18632/oncotarget.28739 Correspondence to - Jordan M. Winter - jordan.winter@UHHospitals.org Abstract video - https://www.youtube.com/watch?v=VeWTcuVmqgM Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28739 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, pancreatic adenocarcinoma, immunotherapy, exceptional responders, microsatellite instability, survival To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

We've got a full house today to talk about the Marvel Tokon Beta, Cronos: The New Dawn, finishing Riven, diving all the way into Sudoku, and how Silksong has done more than live up to the hype.HOLLOW KNIGHT: SILKSONG DISCUSSION FEATURING MINOR SPOILERS runs from roughly 1:24:12 to 1:56:28 (variable depending on how many ads you get beforehand).Today's episode is brought to you by our friends at MSI!For the next month, they'll be offering the Giant Bomb community 10% off regularly priced Intel B860/Z890 motherboards at their US Store: https://us-store.msi.com/ - Just use code "bombcast" at checkout!Big thanks to MSI for their support!

Jeff Grubb and Rachel Kaser start your week with rumors of a new Soul Calibur game, a lot of Silksong frustrations happening post launch, progress being made for Final Fantasy 7 Remake Part 3 and Kingdom Hearts 4, and even more stories to kickstart the week. Today kicks off our month-long partnership with our friends at MSI!For the next month, they'll be offering the Giant Bomb community 10% off regularly priced Intel B860/Z890 motherboards at their US Store: https://us-store.msi.com/ - Just use code "bombcast" at checkout!Big thanks to MSI for their support!

Jeff Grubb is joined by Rhiannon Bevan from TheGamer to chat about Hollow Knight: Silksong and Metal Gear Solid Delta sales, Star Wars Outlaws using a game key card, layoffs at Firaxis, MindsEye traumatizing IOI, and even more stories to end the week! Today kicks off our month-long partnership with our friends at MSI!For the next month, they'll be offering the Giant Bomb community 10% off regularly priced Intel B860/Z890 motherboards at their US Store: https://us-store.msi.com/ - Just use code "bombcast" at checkout!Big thanks to MSI for their support!

Jeff Grubb and Jan Ochoa are here to start your Thursday with stories about Silksong taking down all of the online stores, Wolverine making a supposed appearance at the next State of Play, 007 impressions, and more! Today kicks off our month-long partnership with our friends at MSI!For the next month, they'll be offering the Giant Bomb community 10% off regularly priced Intel B860/Z890 motherboards at their US Store: https://us-store.msi.com/ - Just use code "bombcast" at checkout!Big thanks to MSI for their support!Vote on the Bomb 12! https://docs.google.com/forms/d/e/1FAIpQLSfGEh4EWQ0DuPnFyDBaQooUivEvz4jiphqPQijvKSdtjGoH9w/viewform

Jeff Grubb and Jason Fanelli check in on how Cronos, Everybody's Golf Hot Shots, and Daemon X Machina are reviewing. We also check in on news about Take-Two's involvement in th the Perfect Dark Remaster, Resident Evil: Requiem rumors, and more this Wednesday morning.Today kicks off our month-long partnership with our friends at MSI! For the next month, they'll be offering the Giant Bomb community 10% off regularly priced Intel B860/Z890 motherboards at their US Store: https://us-store.msi.com/ - Just use code "bombcast" at checkout! Big thanks to MSI for their support!

We're rolling out of a three day weekend and straight to the Bombcast! We chat about the Shinobi game, Gears Reloaded, Magic: the Gathering, Slay the Spire, and more games. We also chat about Nintendo having a direct very soon, Sony's live service Fairgames getting having more issues, Capcom and the Switch 2, a price for Hollow Knight: Silksong, and more!Today's episode is brought to you by our friends at MSI!For the next month, they'll be offering the Giant Bomb community 10% off regularly priced Intel B860/Z890 motherboards at their US Store: https://us-store.msi.com/ - Just use code "bombcast" at checkout!Big thanks to MSI for their support!

Jeff Grubb and Lex Luddy round out your week by chatting about a portable PS6 rumor, Final Fantasy XIV cracking down on mods, and the fact that Pragmata is not, in fact, a Mega Man game, MIKE.Today's episode is brought to you by our friends at MSI!For the next month, they'll be offering the Giant Bomb community 10% off regularly priced Intel B860/Z890 motherboards at their US Store: https://us-store.msi.com/ - Just use code "bombcast" at checkout!Big thanks to MSI for their support!

Jeff Grubb and TurboShawn know how to do a podcast with ZERO tech issues, and they're bringing you one today featuring news about Resident Evil Requiem's main character arc, Tim Sweeney blaming devs for Unreal Engine issues, and a Dino Crisis remake happening... And then *not* happening.Today's episode is brought to you by our friends at MSI!For the next month, they'll be offering the Giant Bomb community 10% off regularly priced Intel B860/Z890 motherboards at their US Store: https://us-store.msi.com/ - Just use code "bombcast" at checkout!Big thanks to MSI for their support!

If it feels like med spas are turning into wellness clinics, that's because they kind of are. It's not just about Botox and laser anymore; it's peptides, metabolic health, hormone balancing, and even the little pink pill. In this episode of ASCP Esty Talk, Maggie and Ella discuss how med spas are shifting away from traditional esthetics services and expanding into whole-body health. ASCP Esty Talk with hosts Ella Cressman and Maggie Staszcuk   Produced by Associated Skin Care Professionals (ASCP) for licensed estheticians, ASCP Esty Talk is a weekly podcast, hosted by licensed estheticians, Ella Cressman, ASCP Skin Deep Magazine contributor, and Maggie Staszcuk, ASCP Program Director. We see your passion, innovation, and hard work and are here to support you by providing a platform for networking, advocacy, camaraderie, and education. We aim to inspire you to ask the right questions, find your motivation, and give you the courage to have the professional skin care career you desire.  About Ella Cressman:  Ella Cressman is a licensed esthetician, certified organic formulator, business owner, ingredient junkie, and esthetic cheerleader! As an educator, she enjoys empowering other estheticians and industry professionals to understand skin care from an ingredient standpoint rather than a product-specific view.  In addition to running a skin care practice, Cressman founded a comprehensive consulting group, the HHP Collective, and has consulted for several successful skin care brands.    Connect with Ella Cressman:  Website: www.hhpcollective.com  LinkedIn: linkedin.com/in/ella-cressman-62aa46a    About Maggie Staszcuk:  Maggie Staszcuk serves as the Program Director for ASCP and is the cohost of ASCP Esty Talk podcast. With over 18 years' experience in the esthetics industry, her diverse background includes roles in spa management, spa and med-spa services, and esthetics education. Since becoming a licensed esthetician in 2006, she carries a range of certifications in basic and advanced esthetics. Maggie is dedicated to equipping estheticians with the knowledge and resources they need to thrive in their careers.   Connect with Maggie Staszcuk:  P: 800.789.0411 EXT 1636  E: MStaszcuk@ascpskincare.com    About our Sponsors:   The popular and revolutionary LAMPROBE utilizes radio and high-frequency technology to treat a wide variety of Minor Skin Irregularities™ (MSI)—non-invasively—with instantaneous results. Common conditions treated by the LAMPROBE include: vascular MSI, such as cherry angiomas; dilated capillaries; sebaceous MSI, including cholesterol deposits and milia; and hyperkerantinized MSI, such as keratoses and skin tags.   The LAMPROBE uniquely assists modern, capable, and skilled skin care practitioners to do their work more effectively and with greater client and professional satisfaction. Setting standards in quality, education, and training, the LAMPROBE has become an essential tool enabling skin care practitioners around the world to offer new revenue-enhancing and highly in-demand services.   Website: www.lamprobe.com   Email: info@lamskin.com   Phone: 877-760-2722   Instagram: www.instagram.com/lamprobe   Facebook: www.facebook.com/theLAMPROBE   TiZO Mineral Sunscreens set the standard for aesthetic elegance with tinted and non-tinted formulas for use on virtually all skin types and tones. Our name reflects our commitment: TIZO = Titanium dioxide + Zinc Oxides. All TiZO products are reef-friendly and 100% free of chemical sunscreens, dyes, fragrances, gluten, phthalates, and parabens.  TiZO Photoceutical Skincare is the perfect partner to our sunscreens in the fight against photoaging. These silky, elegant products address tone, texture and hydration while helping to prevent further damage. From our flagship TiZO3 Primer/Sunscreen SPF 40 to our gentle Ultra Zinc formulations to our NEW Advanced Vitamin C+E Serum with Bakuchiol, TIZO has the ideal selection of products to Protect, Repair, and Revitalize skin.    Website: https://tizoskin.com/  Facebook: @tizoskin  Pinterest: @tizoskin  Instagram: @tizoskin  YouTube: @tizoskin     Massage Envy is a national franchisor and does not independently own or operate any of the Massage Envy franchised locations nationwide. The Massage Envy franchise network, through its franchise locations, is the leading provider of massage services. Founded in 2002, Massage Envy now has approximately 1,100 franchise locations in 49 states that have together delivered more than 200 million massages and skin care services. Website: www.massageenvy.com/careers/career-areas/esthetician  Facebook: @MassageEnvyCareers LinkedIn: @MassageEnvy   About Associated Skin Care Professionals (ASCP):    Associated Skin Care Professionals (ASCP) is the nation's largest association for skin care professionals and your ONLY all-inclusive source for professional liability insurance, education, community, and career support. For estheticians at every stage of the journey, ASCP is your essential partner. Get in touch with us today if you have any questions or would like to join and become an ASCP member.  Connect with ASCP:  Website: www.ascpskincare.com  Email: getconnected@ascpskincare.com  Phone: 800-789-0411  Facebook: facebook.com/ASCPskincare  Instagram: @ascpskincare   

Jeff Grubb is joined by Mat Piscatella to talk about July's US video game market highlights report from Circana, Kirby's Switch 2 update and expansion getting glowing reviews, and naturally, development troubles across the industry.Today's episode is brought to you by our friends at MSI!For the next month, they'll be offering the Giant Bomb community 10% off regularly priced Intel B860/Z890 motherboards at their US Store: https://us-store.msi.com/ - Just use code "bombcast" at checkout!Big thanks to MSI for their support!

We're packed with video game talk this week as we talk about Metal Gear Solid Delta, Dan's time with Chibi-Robo, Jan's Gamescom preview of Onimusha, Pragmata, and Resident Evil Requiem, Grubb nearing the end of Expedition 33, and how great Shinobi: Art of Vengeance is! We also recap other Gamescom stories, the delays that Silk Song is causing, and more!Today's episode is brought to you by our friends at MSI!For the next month, they'll be offering the Giant Bomb community 10% off regularly priced Intel B860/Z890 motherboards at their US Store: https://us-store.msi.com/ - Just use code "bombcast" at checkout!Big thanks to MSI for their support!

Get the transparency you deserve and make sure you see the whole story with Ground News. Subscribe to their Vantage plan today and save 40% with our link: https://ground.news/WAN Cool down your PC in style! Check out MSI's MPG CORELIQUID P13 AIO at https://lmg.gg/7UjMo Step confidently into daily life with the ultra-light Vessi Sneakers. Vessi claims they are fully waterproof, and they come with a 1-year warranty with 30-days of worry-free returns. Get 15% off your first pair at https://vessi.com/wanshow at checkout! Get a Circuit Board skin for your device so dbrand can keep messing with Linus at https://dbrand.com/pcb Check out Dell's powerful business laptops at: https://lmg.gg/dellprowan Pick up a Secretlab Titan Evo Ergonomic Gaming Chair today at: https://lmg.gg/secretlabwan Get a special deal on Private Internet Access VPN today at https://www.piavpn.com/LinusWan Purchases made through some store links may provide some compensation to Linus Media Group. NewYork Times Article: https://www.nytimes.com/2025/08/17/business/tiktok-ai-avatars.html Learn more about your ad choices. Visit megaphone.fm/adchoices

What if that breakout isn't just hormonal—and that redness isn't rosacea? In this episode of ASCP Esty Talk, we discuss how big emotions like grief and anger can sneak onto the skin and masquerade as everyday conditions. You'll learn how to spot the difference, what to skip in the treatment room (hint: put down the glycolic), and how to build treatments that meet your clients where they really are—emotionally and physiologically. Plus, we're giving you home-care ideas that go way beyond “use this serum.” This one's for the esties ready to treat more than what meets the eye. ASCP Esty Talk with hosts Ella Cressman and Maggie Staszcuk   Produced by Associated Skin Care Professionals (ASCP) for licensed estheticians, ASCP Esty Talk is a weekly podcast, hosted by licensed estheticians, Ella Cressman, ASCP Skin Deep Magazine contributor, and Maggie Staszcuk, ASCP Program Director. We see your passion, innovation, and hard work and are here to support you by providing a platform for networking, advocacy, camaraderie, and education. We aim to inspire you to ask the right questions, find your motivation, and give you the courage to have the professional skin care career you desire.  About Ella Cressman:  Ella Cressman is a licensed esthetician, certified organic formulator, business owner, ingredient junkie, and esthetic cheerleader! As an educator, she enjoys empowering other estheticians and industry professionals to understand skin care from an ingredient standpoint rather than a product-specific view.  In addition to running a skin care practice, Cressman founded a comprehensive consulting group, the HHP Collective, and has consulted for several successful skin care brands.    Connect with Ella Cressman:  Website: www.hhpcollective.com  LinkedIn: linkedin.com/in/ella-cressman-62aa46a    About Maggie Staszcuk:  Maggie Staszcuk serves as the Program Director for ASCP and is the cohost of ASCP Esty Talk podcast. With over 18 years' experience in the esthetics industry, her diverse background includes roles in spa management, spa and med-spa services, and esthetics education. Since becoming a licensed esthetician in 2006, she carries a range of certifications in basic and advanced esthetics. Maggie is dedicated to equipping estheticians with the knowledge and resources they need to thrive in their careers.   Connect with Maggie Staszcuk:  P: 800.789.0411 EXT 1636  E: MStaszcuk@ascpskincare.com    About our Sponsors:   The popular and revolutionary LAMPROBE utilizes radio and high-frequency technology to treat a wide variety of Minor Skin Irregularities™ (MSI)—non-invasively—with instantaneous results. Common conditions treated by the LAMPROBE include: vascular MSI, such as cherry angiomas; dilated capillaries; sebaceous MSI, including cholesterol deposits and milia; and hyperkerantinized MSI, such as keratoses and skin tags.   The LAMPROBE uniquely assists modern, capable, and skilled skin care practitioners to do their work more effectively and with greater client and professional satisfaction. Setting standards in quality, education, and training, the LAMPROBE has become an essential tool enabling skin care practitioners around the world to offer new revenue-enhancing and highly in-demand services.   Website: www.lamprobe.com   Email: info@lamskin.com   Phone: 877-760-2722   Instagram: www.instagram.com/lamprobe   Facebook: www.facebook.com/theLAMPROBE   TiZO Mineral Sunscreens set the standard for aesthetic elegance with tinted and non-tinted formulas for use on virtually all skin types and tones. Our name reflects our commitment: TIZO = Titanium dioxide + Zinc Oxides. All TiZO products are reef-friendly and 100% free of chemical sunscreens, dyes, fragrances, gluten, phthalates, and parabens.  TiZO Photoceutical Skincare is the perfect partner to our sunscreens in the fight against photoaging. These silky, elegant products address tone, texture and hydration while helping to prevent further damage. From our flagship TiZO3 Primer/Sunscreen SPF 40 to our gentle Ultra Zinc formulations to our NEW Advanced Vitamin C+E Serum with Bakuchiol, TIZO has the ideal selection of products to Protect, Repair, and Revitalize skin.    Website: https://tizoskin.com/  Facebook: @tizoskin  Pinterest: @tizoskin  Instagram: @tizoskin  YouTube: @tizoskin     Massage Envy is a national franchisor and does not independently own or operate any of the Massage Envy franchised locations nationwide. The Massage Envy franchise network, through its franchise locations, is the leading provider of massage services. Founded in 2002, Massage Envy now has approximately 1,100 franchise locations in 49 states that have together delivered more than 200 million massages and skin care services. Website: www.massageenvy.com/careers/career-areas/esthetician  Facebook: @MassageEnvyCareers LinkedIn: @MassageEnvy   About Associated Skin Care Professionals (ASCP):    Associated Skin Care Professionals (ASCP) is the nation's largest association for skin care professionals and your ONLY all-inclusive source for professional liability insurance, education, community, and career support. For estheticians at every stage of the journey, ASCP is your essential partner. Get in touch with us today if you have any questions or would like to join and become an ASCP member.  Connect with ASCP:  Website: www.ascpskincare.com  Email: getconnected@ascpskincare.com  Phone: 800-789-0411  Facebook: facebook.com/ASCPskincare  Instagram: @ascpskincare   

We're back and we're early today! We chat about Grubb starting Expedition 33, Raccoin Pusher, a couple of puzzles with Is This Seat Taken? and Voxelgram 2, and a bunch more games. We also chat about Bioshock 4, an actual Silksong announcement, and other news before Gamescom. Oh...and somehow we talk about War of the Worlds for a while....Today's episode is brought to you by our friends at MSI!For the next month, they'll be offering the Giant Bomb community 10% off regularly priced Intel B860/Z890 motherboards at their US Store: https://us-store.msi.com/ - Just use code "bombcast" at checkout!Big thanks to MSI for their support!

Jeff Grubb is joined by Seth Macy to start your week right, chatting about the fate of Fairgame$, Skate 4 having a rotating soundtrack, and a MASSIVE Kirby Air Riders Direct happening very soon.Today's episode is brought to you by our friends at MSI!For the next month, they'll be offering the Giant Bomb community 10% off regularly priced Intel B860/Z890 motherboards at their US Store: https://us-store.msi.com/ - Just use code "bombcast" at checkout!Big thanks to MSI for their support!

I sit down with Dr Magali Svrcek, Professor of Pathology at the University of Sorbonne in Paris, and she discusses her role as a GI Pathologist.  Dr Svrcek discusses Microsatellite Instability, digital tools and Immunohistochemistry.  Dr Svrcek wrote her script in English, so I in turn wrote my introduction and closing en Francais.  I hope my French is ok.  With fewer Pathologists, especially internationally, digital pathology could be a solution.  In working with Owkin, the collaboration, MsIntuit, an AI diagnostic tool to detect MSI, and is the first to be CE marked.   Colorectal cancer is experiencing an increase internationally as western lifestyle spreads.  African countries, especially sub-Saharan African countries will not have the tools or infrastructure to work with this increase.  Developing a network of experts using digital pathology could mitigate some of these issues.  

BUFFALO, NY – August 15, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on August 13, 2025, titled “Clinical and analytical validation of MI Cancer Seek®, a companion diagnostic whole exome and whole transcriptome sequencing-based comprehensive molecular profiling assay.” In this study, first authors Valeriy Domenyuk and Kasey Benson, along with corresponding author David Spetzler from Caris Life Sciences in Irving, Texas, introduce MI Cancer Seek, an FDA-approved test designed to deliver comprehensive tumor profiling. MI Cancer Seek demonstrated strong concordance with other FDA-approved companion diagnostics and serves as a powerful tool to guide treatment decisions in both adult and pediatric cancer patients. Cancer remains one of the most complex and diverse diseases to treat. With many targeted therapies currently FDA-approved, selecting the right one for a specific patient requires detailed genetic insights. MI Cancer Seek addresses this need by analyzing both DNA and RNA from a single tumor sample. The tool identifies key biomarkers linked to FDA-approved treatments for several major cancers, including breast, lung, colon, melanoma, and endometrial cancers. One of the most significant strengths of MI Cancer Seek is its ability to deliver accurate and reliable results from minimal tissue input (50 ng). Even when analyzing formalin-fixed paraffin-embedded samples, which are widely used but often degraded, the test maintained high levels of accuracy. It successfully detected important genetic alterations such as PIK3CA, EGFR, BRAF, and KRAS/NRAS mutations and measured tumor mutational burden (TMB) and microsatellite instability (MSI), both of which are key indicators for immunotherapy response. In clinical comparisons, the test achieved over 97% agreement with other FDA-approved diagnostic tools, confirming its reliability in detecting critical biomarkers. Notably, it showed near-perfect accuracy in identifying MSI status in colorectal and endometrial cancers. The researchers also demonstrated that the test maintains precision across different lab conditions and varying DNA input levels, confirming its robustness for routine clinical use. Beyond its role as a companion diagnostic, MI Cancer Seek incorporates additional features developed under its predecessor, MI Tumor Seek Hybrid. These include detection of homologous recombination deficiency, structural variants, and cancer-related viruses. It also includes advanced tools such as the Genomic Probability Score for identifying the tissue of origin in cancers of unknown primary, as well as a gene signature to guide first-line chemotherapy in colorectal cancer. “One limitation to be considered is the low PPA for ERBB2 CNA detection.” By offering deeper genetic insights from a single, small sample, MI Cancer Seek has the potential to streamline diagnostics, reduce testing costs, and connect patients to effective therapies more quickly. As precision medicine continues to expand, this assay stands out as a comprehensive and efficient solution for meeting the evolving needs of modern oncology. DOI - https://doi.org/10.18632/oncotarget.28761 Correspondence to - David Spetzler - dspetzler@carisls.com Video short - https://www.youtube.com/watch?v=D4hd2FxCYY8 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Skin care has been the reigning queen of beauty for years—but that crown may be slipping. Is this just a phase or a sign that consumer behavior is evolving? In this episode of ASCP Esty Talk, Maggie and Ella unpack the so-called “skin care recession,” a major industry shift showing a slowdown in skin care sales and a rise in fragrance and makeup. Tune in as we explore what's driving the trend, how it's showing up in the treatment room, and what estheticians need to know to stay ahead. ASCP Esty Talk with hosts Ella Cressman and Maggie Staszcuk   Produced by Associated Skin Care Professionals (ASCP) for licensed estheticians, ASCP Esty Talk is a weekly podcast, hosted by licensed estheticians, Ella Cressman, ASCP Skin Deep Magazine contributor, and Maggie Staszcuk, ASCP Program Director. We see your passion, innovation, and hard work and are here to support you by providing a platform for networking, advocacy, camaraderie, and education. We aim to inspire you to ask the right questions, find your motivation, and give you the courage to have the professional skin care career you desire.  About Ella Cressman:  Ella Cressman is a licensed esthetician, certified organic formulator, business owner, ingredient junkie, and esthetic cheerleader! As an educator, she enjoys empowering other estheticians and industry professionals to understand skin care from an ingredient standpoint rather than a product-specific view.  In addition to running a skin care practice, Cressman founded a comprehensive consulting group, the HHP Collective, and has consulted for several successful skin care brands.    Connect with Ella Cressman:  Website: www.hhpcollective.com  LinkedIn: linkedin.com/in/ella-cressman-62aa46a    About Maggie Staszcuk:  Maggie Staszcuk serves as the Program Director for ASCP and is the cohost of ASCP Esty Talk podcast. With over 18 years' experience in the esthetics industry, her diverse background includes roles in spa management, spa and med-spa services, and esthetics education. Since becoming a licensed esthetician in 2006, she carries a range of certifications in basic and advanced esthetics. Maggie is dedicated to equipping estheticians with the knowledge and resources they need to thrive in their careers.   Connect with Maggie Staszcuk:  P: 800.789.0411 EXT 1636  E: MStaszcuk@ascpskincare.com    About our Sponsors:   The popular and revolutionary LAMPROBE utilizes radio and high-frequency technology to treat a wide variety of Minor Skin Irregularities™ (MSI)—non-invasively—with instantaneous results. Common conditions treated by the LAMPROBE include: vascular MSI, such as cherry angiomas; dilated capillaries; sebaceous MSI, including cholesterol deposits and milia; and hyperkerantinized MSI, such as keratoses and skin tags.   The LAMPROBE uniquely assists modern, capable, and skilled skin care practitioners to do their work more effectively and with greater client and professional satisfaction. Setting standards in quality, education, and training, the LAMPROBE has become an essential tool enabling skin care practitioners around the world to offer new revenue-enhancing and highly in-demand services.   Website: www.lamprobe.com   Email: info@lamskin.com   Phone: 877-760-2722   Instagram: www.instagram.com/lamprobe   Facebook: www.facebook.com/theLAMPROBE   TiZO Mineral Sunscreens set the standard for aesthetic elegance with tinted and non-tinted formulas for use on virtually all skin types and tones. Our name reflects our commitment: TIZO = Titanium dioxide + Zinc Oxides. All TiZO products are reef-friendly and 100% free of chemical sunscreens, dyes, fragrances, gluten, phthalates, and parabens.  TiZO Photoceutical Skincare is the perfect partner to our sunscreens in the fight against photoaging. These silky, elegant products address tone, texture and hydration while helping to prevent further damage. From our flagship TiZO3 Primer/Sunscreen SPF 40 to our gentle Ultra Zinc formulations to our NEW Advanced Vitamin C+E Serum with Bakuchiol, TIZO has the ideal selection of products to Protect, Repair, and Revitalize skin.    Website: https://tizoskin.com/  Facebook: @tizoskin  Pinterest: @tizoskin  Instagram: @tizoskin  YouTube: @tizoskin     Massage Envy is a national franchisor and does not independently own or operate any of the Massage Envy franchised locations nationwide. The Massage Envy franchise network, through its franchise locations, is the leading provider of massage services. Founded in 2002, Massage Envy now has approximately 1,100 franchise locations in 49 states that have together delivered more than 200 million massages and skin care services. Website: www.massageenvy.com/careers/career-areas/esthetician  Facebook: @MassageEnvyCareers LinkedIn: @MassageEnvy   About Associated Skin Care Professionals (ASCP):    Associated Skin Care Professionals (ASCP) is the nation's largest association for skin care professionals and your ONLY all-inclusive source for professional liability insurance, education, community, and career support. For estheticians at every stage of the journey, ASCP is your essential partner. Get in touch with us today if you have any questions or would like to join and become an ASCP member.  Connect with ASCP:  Website: www.ascpskincare.com  Email: getconnected@ascpskincare.com  Phone: 800-789-0411  Facebook: facebook.com/ASCPskincare  Instagram: @ascpskincare 

What happens when your business starts to feel like your whole identity? When you are your brand, where's the line between personal and professional? In this episode of ASCP Esty Talk, Maggie and Ella talk about the overlap between who you are and what you do—and when that overlap becomes too much, how to set boundaries and reconnect with yourself outside the treatment room. ASCP Esty Talk with hosts Ella Cressman and Maggie Staszcuk   Produced by Associated Skin Care Professionals (ASCP) for licensed estheticians, ASCP Esty Talk is a weekly podcast, hosted by licensed estheticians, Ella Cressman, ASCP Skin Deep Magazine contributor, and Maggie Staszcuk, ASCP Program Director. We see your passion, innovation, and hard work and are here to support you by providing a platform for networking, advocacy, camaraderie, and education. We aim to inspire you to ask the right questions, find your motivation, and give you the courage to have the professional skin care career you desire.  About Ella Cressman:  Ella Cressman is a licensed esthetician, certified organic formulator, business owner, ingredient junkie, and esthetic cheerleader! As an educator, she enjoys empowering other estheticians and industry professionals to understand skin care from an ingredient standpoint rather than a product-specific view.  In addition to running a skin care practice, Cressman founded a comprehensive consulting group, the HHP Collective, and has consulted for several successful skin care brands.    Connect with Ella Cressman:  Website: www.hhpcollective.com  LinkedIn: linkedin.com/in/ella-cressman-62aa46a    About Maggie Staszcuk:  Maggie Staszcuk serves as the Program Director for ASCP and is the cohost of ASCP Esty Talk podcast. With over 18 years' experience in the esthetics industry, her diverse background includes roles in spa management, spa and med-spa services, and esthetics education. Since becoming a licensed esthetician in 2006, she carries a range of certifications in basic and advanced esthetics. Maggie is dedicated to equipping estheticians with the knowledge and resources they need to thrive in their careers.   Connect with Maggie Staszcuk:  P: 800.789.0411 EXT 1636  E: MStaszcuk@ascpskincare.com    About our Sponsors:   The popular and revolutionary LAMPROBE utilizes radio and high-frequency technology to treat a wide variety of Minor Skin Irregularities™ (MSI)—non-invasively—with instantaneous results. Common conditions treated by the LAMPROBE include: vascular MSI, such as cherry angiomas; dilated capillaries; sebaceous MSI, including cholesterol deposits and milia; and hyperkerantinized MSI, such as keratoses and skin tags.   The LAMPROBE uniquely assists modern, capable, and skilled skin care practitioners to do their work more effectively and with greater client and professional satisfaction. Setting standards in quality, education, and training, the LAMPROBE has become an essential tool enabling skin care practitioners around the world to offer new revenue-enhancing and highly in-demand services. Website: www.lamprobe.com Email: info@lamskin.com Phone: 877-760-2722 Instagram: www.instagram.com/lamprobe Facebook: www.facebook.com/theLAMPROBE   TiZO Mineral Sunscreens set the standard for aesthetic elegance with tinted and non-tinted formulas for use on virtually all skin types and tones. Our name reflects our commitment: TIZO = Titanium dioxide + Zinc Oxides. All TiZO products are reef-friendly and 100% free of chemical sunscreens, dyes, fragrances, gluten, phthalates, and parabens.  TiZO Photoceutical Skincare is the perfect partner to our sunscreens in the fight against photoaging. These silky, elegant products address tone, texture and hydration while helping to prevent further damage. From our flagship TiZO3 Primer/Sunscreen SPF 40 to our gentle Ultra Zinc formulations to our NEW Advanced Vitamin C+E Serum with Bakuchiol, TIZO has the ideal selection of products to Protect, Repair, and Revitalize skin.    Website: https://tizoskin.com/  Facebook: @tizoskin  Pinterest: @tizoskin  Instagram: @tizoskin  YouTube: @tizoskin     Massage Envy is a national franchisor and does not independently own or operate any of the Massage Envy franchised locations nationwide. The Massage Envy franchise network, through its franchise locations, is the leading provider of massage services. Founded in 2002, Massage Envy now has approximately 1,100 franchise locations in 49 states that have together delivered more than 200 million massages and skin care services. Website: www.massageenvy.com/careers/career-areas/esthetician  Facebook: @MassageEnvyCareers LinkedIn: @MassageEnvy   About Associated Skin Care Professionals (ASCP):    Associated Skin Care Professionals (ASCP) is the nation's largest association for skin care professionals and your ONLY all-inclusive source for professional liability insurance, education, community, and career support. For estheticians at every stage of the journey, ASCP is your essential partner. Get in touch with us today if you have any questions or would like to join and become an ASCP member.  Connect with ASCP:  Website: www.ascpskincare.com  Email: getconnected@ascpskincare.com  Phone: 800-789-0411  Facebook: facebook.com/ASCPskincare  Instagram: @ascpskincare   

“Colorectal cancer treatment is not just about eliminating a disease. It's about preserving life quality and empowering patients through every phase. So I think nurses are really at the forefront that we can do that in the oncology nursing space. So from early detection to survivorship, the journey is deeply personal. Precision medicine, compassionate care, and informed decision-making are reshaping outcomes. Treatment's just not about protocols. It's about people,” ONS member Kris Mathey, DNP, APRN-CNP, AOCNP®, gastrointestinal medical oncology nurse practitioner at The James Cancer Hospital of The Ohio State University Wexner Medical Center in Columbus, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about colorectal cancer treatment.  Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 1.0 contact hour of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 1, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the treatment of colorectal cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 370: Colorectal Cancer Screening, Early Detection, and Disparities Episode 153: Metastatic Colorectal Cancer Has More Treatment Options Than Ever Before ONS Voice articles: Colorectal Cancer Prevention, Screening, Treatment, and Survivorship Recommendations Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) How Liquid Biopsies Are Used in Cancer Treatment Selection Oncology Drug Reference Sheet: 5-Fluorouracil Oncology Drug Reference Sheet: Oxaliplatin What Is a Liquid Biopsy? Clinical Journal of Oncology Nursing article: Colorectal Cancer in Young Adults: Considerations for Oncology Nurses Oncology Nursing Forum article: Neurotoxic Side Effects Early in the Oxaliplatin Treatment Period in Patients With Colorectal Cancer ONS Colorectal Cancer Learning Library ONS Biomarker Database (filtered by colorectal cancer) ONS Peripheral Neuropathy Symptom Interventions American Cancer Society colorectal cancer resources CancerCare Colorectal Cancer Alliance Colorectal Cancer Resource and Action Network Fight Colorectal Cancer National Comprehensive Cancer Network To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Colorectal cancer has several different types, but there is one that dominates the landscape, and that is adenocarcinoma. So I think most of us have heard that. It's fairly common, and it accounts for about 95% of all colorectal cancers. It begins in the glandular cells lining the colon or rectum and often develops from polyps, in particular adenomatous polyps.” TS 1:41 “One of the biomarkers that we'll most commonly hear about is KRAS or NRAS mutations. This indicates tumor genetics, and these mutations suggest resistance to our EGFR inhibitors such as cetuximab. BRAF mutation or V600E is a more aggressive tumor subtype, and those may respond to our BRAF targeted therapy. … And then our MSI-high or MMR-deficient—microsatellite instability or mismatch repair deficiency—that really predicts an immunotherapy response and may indicate Lynch syndrome, which is a huge genetic component that takes a whole other level of counseling and genetic testing with our patients as well.” TS 6:02 “Polypectomy or a local excision—that removes our small tumors or polyps during that colonoscopy. And that's what's used for those stage 0 or early stage I cancers. A colectomy removes part or all of the colon. This may be open or laparoscopic. It can include a hemicolectomy, a segmental resection, or a total colectomy, so where you take out the entire part of the colon. A proctectomy removes part or all of the rectum. This may include a low anterior resection, also known as an LAR … or an abdominal perineal resection, which is an APR. … Colostomy or ileostomy—that diverts the stool to an external bag via stoma. Sometimes this is temporary or permanent depending on the type of surgery.” TS 14:11 “We'll have our patients say, ‘Hey, I want immunotherapy therapy. I see commercials on it that it works so well.' We have to make sure that these patients are good candidates for it, also that we're treating them adequately. We need to make sure that they have those biomarkers, so as I mentioned, the MSI-high or MMR tumors. Our MSS-stable tumors—they may benefit from newer combinations or clinical trials. Metastatic disease—immunotherapy may be used alone or with other treatments. And then in the neoadjuvant setting, some trials are really showing promising results using immunotherapy prior to surgery.” TS 25:38 “Antibody-drug conjugates are really an exciting frontier in all cancer treatments as well as colorectal cancer treatment. This is used mainly for patients with advanced or treatment-resistant disease, and these therapies combine the targeted power of monoclonal antibodies with the cell-killing ability of potent chemotherapy agents. They're still on the horizon for the most part in colorectal cancer. However, there is only one approved antibody-drug conjugate, or ADC, at this time, and that's trastuzumab deruxtecan, or Enhertu. That's approved for any solid tumor, such as colorectal cancer with HER2 IHC 3+. So again, looking back at that pathology in those markers, making sure that you have that HER2 mutation and that IHC.” TS 35:00 “There are a few myths going around about colorectal cancer treatment that can lead to confusion or even delayed care. One myth is only older men get colorectal cancer. As you heard me talk in my previous podcast on screening, unfortunately, this isn't necessarily true. Colorectal cancer affects both men and women and our cases in the younger population are rising. So our screening guidelines have changed to age 45 because we are seeing it in the younger population.” TS 45:54

The boys discuss Patch 25.14, Tilt Brackets, MSI, emails and more on episode 699 of Leaguecast! Email us - mail@leaguecastpodcast.com   Support us - https://www.patreon.com/leaguecast  Tweet us - https://twitter.com/leaguecast   Facebook - https://www.facebook.com/Leaguecast/   Join Our Discord - https://discord.gg/leaguecast  Visit our Website - https://leaguecastpodcast.com/

Welcome back to a brand new episode of The Dive Driven by Kia. Chronicler joins Azael and Kobe right after the insanity of the MSI Finals! They discuss the future of Fearless within the competitive scene, cover FlyQuest's intense series against BilliBilli Gaming, and reflect on their experience at MSI. Thank you to the fans who showed up for an epic MSI in Vancouver, and for all the listeners who tuned into these episodes!With MSI now concluded, get ready as the LTA North returns July 26th with FlyQuest taking on Disguised at 1PM PT/4PM ET, followed by Cloud9 vs Lyon.Timestamps:0:00 Intro and T1 vs Gen.G Finals Recap 21:46 Doran was not the problem27:29 FlyQuest vs BiliBili Gaming42:52 MSI Memories & Fan Appreciation

Welcome back to a brand new episode of The Dive, Driven by Kia. MSI 2025 is already delivering some exciting games, and the crew is here to break it all down. They take a look at standout moments from every region, including an unforgettable showdown between NA and EU, an impressive showing from the LCP, and absolute bangers featuring LCK and LPL powerhouses. The team also looks ahead to Week 2's high stakes matchups, spicy storylines, and discusses which teams are heating up and which ones might be in trouble.Who's looking the strongest? Who needs to bounce back? Let us know what you think in the comments below!MSI continues July 7 at 5PM PT/8PM ET. Timestamps:0:00 - Intro & Farewell to Europe3:23 - Champion Win rates at MSI9:31 - FlyQuest vs G2 Esports Recap26:05 - Gen.G vs Anyone's Legend Recap30:37 - The Evolution of Champion Strategies44:00 - Movistar KOI vs CTBC Flying Oyster Recap46:46 - T1 vs BLG Recap1:08:59 - CTBC Flying Oyster's Impressive Showing 1:17:43 - CTBC Flying Oysters vs Anyone's Legend Preview1:29:57 - FlyQuest vs BiliBili Gaming Preview1:37:42 - Gen.G vs T1 Preview